European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact
Guidelines

Urological Infections

Want to read the guideline in your own time? Download the PDF

Download full guideline

Looking for a quick overview? Check the pocket guidelines.

Download pocket guidelines
Full text guidelineSummary of ChangesPublications & AppendicesPanelRelated content
No results found
  1. Introduction
  2. Methods
  3. The Guideline
  4. References
  5. Conflict Of Interest
  6. Citation Information
  7. Copyright And Terms Of Use
4. References
  • 1. Introduction
  • 2. Methods
  • 3. The Guideline
  • 4. References
  • 5. Conflict Of Interest
  • 6. Citation Information
  • 7. Copyright And Terms Of Use
  • No elements found. Consider changing the search query.
  • List is empty.

4. REFERENCES

1.Radmayr, C., et al. EAU Guidelines on Paediatric Urology. In: EAU Guidelines, edition presented at the annual EAU Congress Madrid 2025. ISBN 978-94-92671-29-5.

https://uroweb.org/guidelines/paediatric-urology

2.Blok, B., et al. EAU Guidelines on Neuro-urology. In: EAU Guidelines, edition presented at the annual EAU Congress Madrid 2025. ISBN 978-94-92671-29-5.

https://uroweb.org/guidelines/archive/neuro-urology

3.Phillips, B., et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March Updated 2009. 1998.

https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009

4.Guyatt, G.H., et al. Going from evidence to recommendations. BMJ, 2008. 336: 1049.

https://www.ncbi.nlm.nih.gov/pubmed/18467413

5.Horan, T.C., et al. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control, 2008. 36: 309.

https://www.ncbi.nlm.nih.gov/pubmed/18538699

6.Rubin, R.H., et al. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis, 1992. 15 Suppl 1: S216.

https://www.ncbi.nlm.nih.gov/pubmed/1477233

7.Rubin, R.H., et al. General guidelines for the evaluation of new anti-infective drugs for the treatment of urinary tract infection. Clin Infect Dis. Taukirchen, Germany., 1993: 240.

https://www.ncbi.nlm.nih.gov/pubmed/1457636

8.FDA. Guidance for Industry Uncomplicated Urinary Tract Infections — Developing Antimicrobial Drugs for Treatment. 2015.

https://www.fda.gov/media/129531/download

9.FDA. Complicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry 2018.

https://www.fda.gov/media/71313/download

10.Bell, B.G., et al. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis, 2014. 14: 13.

https://www.ncbi.nlm.nih.gov/pubmed/24405683

11.WHO. Antimicrobial resistance: global report on surveillance 2014.

https://www.who.int/publications/i/item/9789241564748

12.Hulscher, M.E., et al. Antibiotic prescribing in hospitals: a social and behavioural scientific approach. Lancet Infect Dis, 2010. 10: 167.

https://www.ncbi.nlm.nih.gov/pubmed/20185095

13.Goff, D.A., et al. A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail. Lancet Infect Dis, 2017. 17: e56.

https://www.ncbi.nlm.nih.gov/pubmed/27866945

14.Dellit, T.H., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis, 2007. 44: 159.

https://www.ncbi.nlm.nih.gov/pubmed/17173212

15.Davey, P., et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev, 2017. 2: CD003543.

https://www.ncbi.nlm.nih.gov/pubmed/28178770

16.Cefai, C., et al. Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use. NICE Guidelines, 2015.

https://www.nice.org.uk/guidance/ng15

17.Schuts, E.C., et al. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis, 2016. 16: 847.

https://www.ncbi.nlm.nih.gov/pubmed/26947617

18.Hermanides, H.S., et al. Development of quality indicators for the antibiotic treatment of complicated urinary tract infections: a first step to measure and improve care. Clin Infect Dis, 2008. 46: 703.

https://www.ncbi.nlm.nih.gov/pubmed/18230045

19.Spoorenberg, V., et al. Appropriate antibiotic use for patients with urinary tract infections reduces length of hospital stay. Clin Infect Dis, 2014. 58: 164.

https://www.ncbi.nlm.nih.gov/pubmed/24158412

20.Lutay, N., et al. Bacterial control of host gene expression through RNA polymerase II. J Clin Invest, 2013. 123: 2366.

https://www.ncbi.nlm.nih.gov/pubmed/23728172

21.Hansson, S., et al. Untreated asymptomatic bacteriuria in girls: II--Effect of phenoxymethylpenicillin and erythromycin given for intercurrent infections. BMJ, 1989. 298: 856.

https://www.ncbi.nlm.nih.gov/pubmed/2497823

22.Cai, T., et al. The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat? Clin Infect Dis, 2012. 55: 771.

https://www.ncbi.nlm.nih.gov/pubmed/22677710

23.Nicolle, L.E., et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis, 2005. 40: 643.

https://www.ncbi.nlm.nih.gov/pubmed/15714408

24.Kass, E.H. Asymptomatic infections of the urinary tract. Trans Assoc Am Physicians, 1956. 69: 56.

https://www.ncbi.nlm.nih.gov/pubmed/13380946

25.Gleckman, R., et al. Reliability of a single urine culture in establishing diagnosis of asymptomatic bacteriuria in adult males. J Clin Microbiol, 1979. 9: 596.

https://www.ncbi.nlm.nih.gov/pubmed/383746

26.Kunin CM. Urinary tract infections: detection, prevention and management. 5th ed. Baltimore: Williams and Wilkins., 1997.

https://link.springer.com/article/10.1007/BF02771849

27.Warren, J.W., et al. A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters. J Infect Dis, 1982. 146: 719.

https://www.ncbi.nlm.nih.gov/pubmed/6815281

28.Hooton, T.M., et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis, 2010. 50: 625.

https://www.ncbi.nlm.nih.gov/pubmed/20175247

29.Koves, B., et al. Benefits and Harms of Treatment of Asymptomatic Bacteriuria: A Systematic Review and Meta-analysis by the European Association of Urology Urological Infection Guidelines Panel. Eur Urol, 2017. 72: 865.

https://www.ncbi.nlm.nih.gov/pubmed/28754533

30.Tencer, J. Asymptomatic bacteriuria--a long-term study. Scand J Urol Nephrol, 1988. 22: 31.

https://www.ncbi.nlm.nih.gov/pubmed/3387908

31.Asscher, A.W., et al. The clinical significance of asymptomatic bacteriuria in the nonpregnant woman. J Infect Dis, 1969. 120: 17.

https://www.ncbi.nlm.nih.gov/pubmed/5803281

32.Elder, H.A., et al. The natural history of asymptomatic bacteriuria during pregnancy: the effect of tetracycline on the clinical course and the outcome of pregnancy. Am J Obstet Gynecol, 1971. 111: 441.

https://www.ncbi.nlm.nih.gov/pubmed/4937729

33.Elder, H.A., et al. Use of sulfasymazine in the treatment of bacteriuria of pregnancy. Antimicrob Agents Chemother (Bethesda), 1966. 6: 142.

https://www.ncbi.nlm.nih.gov/pubmed/4862162

34.Gold, E.M., et al. Asymptomatic bacteriuria during pregnancy. Obstet Gynecol, 1966. 27: 206.

https://www.ncbi.nlm.nih.gov/pubmed/5325600

35.Kass, E.H. Pyelonephritis and bacteriuria. A major problem in preventive medicine. Ann Intern Med, 1962. 56: 46.

https://www.ncbi.nlm.nih.gov/pubmed/14454174

36.Kincaid-Smith, P., et al. Bacteriuria in Pregnancy. Lancet, 1965. 1: 395.

https://www.ncbi.nlm.nih.gov/pubmed/14238090

37.Little, P.J. The incidence of urinary infection in 5000 pregnant women. Lancet, 1966. 2: 925.

https://www.ncbi.nlm.nih.gov/pubmed/4162367

38.Mulla, N. Bacteriuria in pregnancy. Obstet Gynecol, 1960. 16: 89.

https://www.ncbi.nlm.nih.gov/pubmed/14425118

39.Pathak, U.N., et al. Bacteriuria of pregnancy: results of treatment. J Infect Dis, 1969. 120: 91.

https://www.ncbi.nlm.nih.gov/pubmed/5816817

40.Robertson, J.G., et al. The managment and complications of asymptomatic bacteriuria in pregnancy. Report of a study on 8,275 patients. J Obstet Gynaecol Br Commonw, 1968. 75: 59.

https://www.ncbi.nlm.nih.gov/pubmed/5635245

41.Thomsen, A.C., et al. Antibiotic elimination of group-B streptococci in urine in prevention of preterm labour. Lancet, 1987. 1: 591.

https://www.ncbi.nlm.nih.gov/pubmed/2881132

42.Williams, G.L., et al. Urinary concentrating ability in women with asymptomatic bacteriuria in pregnancy. Br Med J, 1969. 3: 212.

https://www.ncbi.nlm.nih.gov/pubmed/5792611

43.Wren, B.G. Subclinical renal infection and prematurity. Med J Aust, 1969. 2: 596.

https://www.ncbi.nlm.nih.gov/pubmed/5388374

44.Kazemier, B.M., et al. Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a prospective cohort study with an embedded randomised controlled trial. Lancet Infect Dis, 2015. 15: 1324.

https://www.ncbi.nlm.nih.gov/pubmed/26255208

45.Henderson, J.T., et al. Screening for Asymptomatic Bacteriuria in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA, 2019. 322: 1195.

https://www.ncbi.nlm.nih.gov/pubmed/31550037

46.Smaill, F.M., et al. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev, 2019. 2019: CD000490.

https://www.ncbi.nlm.nih.gov/pubmed/31765489

47.Wingert, A., et al. Asymptomatic bacteriuria in pregnancy: systematic reviews of screening and treatment effectiveness and patient preferences. BMJ Open, 2019. 9: e021347.

https://www.ncbi.nlm.nih.gov/pubmed/30872538

48.Christopher, L.J., et al. A trial of hippramine in the treatment of bacteriuria of pregnancy. Ir J Med Sci, 1969. 8: 331.

https://www.ncbi.nlm.nih.gov/pubmed/5806178

49.Reeves, D.S. Laboratory and clinical studies with sulfametopyrazine as a treatment for bacteriuria in pregnancy. J Antimicrob Chemother, 1975. 1: 171.

https://www.ncbi.nlm.nih.gov/pubmed/1100589

50.Whalley, P.J., et al. Short-term versus continuous antimicrobial therapy for asymptomatic bacteriuria in pregnancy. Obstet Gynecol, 1977. 49: 262.

https://www.ncbi.nlm.nih.gov/pubmed/320525

51.Bint, A., et al. A comparative trial of pivmecillinam and ampicillin in bacteriuria of pregnancy. Infection, 1979. 7: 290.

https://www.ncbi.nlm.nih.gov/pubmed/232697

52.Harris, R.E., et al. Single-dose antimicrobial therapy for asymptomatic bacteriuria during pregnancy. Obstet Gynecol, 1982. 59: 546.

https://www.ncbi.nlm.nih.gov/pubmed/7070725

53.Bailey, R.R., et al. Comparison of single dose with a 5-day course of co-trimoxazole for asymptomatic (covert) bacteriuria of pregnancy. Aust N Z J Obstet Gynaecol, 1983. 23: 139.

https://www.ncbi.nlm.nih.gov/pubmed/6606421

54.Masterton, R.G., et al. Single-dose amoxycillin in the treatment of bacteriuria in pregnancy and the puerperium--a controlled clinical trial. Br J Obstet Gynaecol, 1985. 92: 498.

https://www.ncbi.nlm.nih.gov/pubmed/3888250

55.Pedler, S.J., et al. Comparative study of amoxicillin-clavulanic acid and cephalexin in the treatment of bacteriuria during pregnancy. Antimicrob Agents Chemother, 1985. 27: 508.

https://www.ncbi.nlm.nih.gov/pubmed/4004191

56.Campbell-Brown, M., et al. Is screening for bacteriuria in pregnancy worth while? Br Med J (Clin Res Ed), 1987. 294: 1579.

https://www.ncbi.nlm.nih.gov/pubmed/3113538

57.Pregazzi, R., et al. [Single-dose antibiotic therapy of asymptomatic bacteriuria in pregnancy. Results and complications]. Minerva Ginecol, 1987. 39: 289.

https://www.ncbi.nlm.nih.gov/pubmed/3601207

58.Gerstner, G.J., et al. Amoxicillin in the treatment of asymptomatic bacteriuria in pregnancy: a single dose of 3 g amoxicillin versus a 4-day course of 3 doses 750 mg amoxicillin. Gynecol Obstet Invest, 1989. 27: 84.

https://www.ncbi.nlm.nih.gov/pubmed/2659442

59.Olsen, L., et al. Single-dose versus six-day therapy with sulfamethizole for asymptomatic bacteriuria during pregnancy. A prospective randomised study. Dan Med Bull, 1989. 36: 486.

https://www.ncbi.nlm.nih.gov/pubmed/2680315

60.Thoumsin, H., et al. Single dose fosfomycin trometamol versus multiple dose nitrofurantoin in pregnant women with bacteriuria: preliminary results. Infection, 1990. 18 Suppl 2: S94.

https://www.ncbi.nlm.nih.gov/pubmed/2286469

61.Bayrak, O., et al. Is single-dose fosfomycin trometamol a good alternative for asymptomatic bacteriuria in the second trimesterof pregnancy? Int Urogynecol J Pelvic Floor Dysfunct, 2007. 18: 525.

https://www.ncbi.nlm.nih.gov/pubmed/16941068

62.Estebanez, A., et al. Fosfomycin in a single dose versus a 7-day course of amoxicillin-clavulanate for the treatment of asymptomatic bacteriuria during pregnancy. Eur J Clin Microbiol Infect Dis, 2009. 28: 1457.

https://www.ncbi.nlm.nih.gov/pubmed/19768649

63.Lumbiganon, P., et al. One-day compared with 7-day nitrofurantoin for asymptomatic bacteriuria in pregnancy: a randomized controlled trial. Obstet Gynecol, 2009. 113: 339.

https://www.ncbi.nlm.nih.gov/pubmed/19155904

64.Widmer, M., et al. Duration of treatment for asymptomatic bacteriuria during pregnancy. Cochrane Database Syst Rev, 2015. 2015: CD000491.

https://www.ncbi.nlm.nih.gov/pubmed/26560337

65.Wang, T., et al. Comparison of single-dose fosfomycin tromethamine and other antibiotics for lower uncomplicated urinary tract infection in women and asymptomatic bacteriuria in pregnant women: A systematic review and meta-analysis. Int J Antimicrob Agents, 2020. 56: 106018.

https://www.ncbi.nlm.nih.gov/pubmed/32417205

66.Zhanel, G.G., et al. Asymptomatic bacteriuria in patients with diabetes mellitus. Rev Infect Dis, 1991. 13: 150.

https://www.ncbi.nlm.nih.gov/pubmed/2017615

67.Harding, G.K., et al. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med, 2002. 347: 1576.

https://www.ncbi.nlm.nih.gov/pubmed/12432044

68.Mody, L., et al. Urinary tract infections in older women: a clinical review. JAMA, 2014. 311: 844.

https://www.ncbi.nlm.nih.gov/pubmed/24570248

69.Boscia, J.A., et al. Therapy vs no therapy for bacteriuria in elderly ambulatory nonhospitalized women. JAMA, 1987. 257: 1067.

https://www.ncbi.nlm.nih.gov/pubmed/3806896

70.Abrutyn, E., et al. Does asymptomatic bacteriuria predict mortality and does antimicrobial treatment reduce mortality in elderly ambulatory women? Ann Intern Med, 1994. 120: 827.

https://www.ncbi.nlm.nih.gov/pubmed/7818631

71.Abrutyn, E., et al. Does treatment of asymptomatic bacteriuria in older ambulatory women reduce subsequent symptoms of urinary tract infection? J Am Geriatr Soc, 1996. 44: 293.

https://www.ncbi.nlm.nih.gov/pubmed/8600199

72.Nicolle, L.E., et al. Prospective randomized comparison of therapy and no therapy for asymptomatic bacteriuria in institutionalized elderly women. Am J Med, 1987. 83: 27.

https://www.ncbi.nlm.nih.gov/pubmed/3300325

73.Nicolle, L.E. Asymptomatic bacteriuria in the elderly. Infect Dis Clin North Am, 1997. 11: 647.

https://www.ncbi.nlm.nih.gov/pubmed/9378928

74.Silver, S.A., et al. Positive urine cultures: A major cause of inappropriate antimicrobial use in hospitals? Can J Infect Dis Med Microbiol, 2009. 20: 107.

https://www.ncbi.nlm.nih.gov/pubmed/21119801

75.Trautner, B.W. Asymptomatic bacteriuria: when the treatment is worse than the disease. Nat Rev Urol, 2011. 9: 85.

https://www.ncbi.nlm.nih.gov/pubmed/22143416

76.Nicolle, L.E., et al. Bacteriuria in elderly institutionalized men. N Engl J Med, 1983. 309: 1420.

https://www.ncbi.nlm.nih.gov/pubmed/6633618

77.Potts, L., et al. A double-blind comparative study of norfloxacin versus placebo in hospitalised elderly patients with asymptomatic bacteriuria. Arch Gerontol Geriatr, 1996. 23: 153.

https://www.ncbi.nlm.nih.gov/pubmed/15374159

78.Renneberg, J., et al. Single-day treatment with trimethoprim for asymptomatic bacteriuria in the elderly patient. J Urol, 1984. 132: 934.

https://www.ncbi.nlm.nih.gov/pubmed/6387184

79.Ouslander, J.G., et al. Does eradicating bacteriuria affect the severity of chronic urinary incontinence in nursing home residents? Ann Intern Med, 1995. 122: 749.

https://www.ncbi.nlm.nih.gov/pubmed/7717597

80.Krzyzaniak, N., et al. Antibiotics versus no treatment for asymptomatic bacteriuria in residents of aged care facilities: a systematic review and meta-analysis. Br J Gen Pract, 2022. 72: e649.

https://www.ncbi.nlm.nih.gov/pubmed/35940886

81.Moradi, M., et al. Effect of antibiotic therapy on asymptomatic bacteriuria in kidney transplant recipients. Urol J, 2005. 2: 32.

https://www.ncbi.nlm.nih.gov/pubmed/17629893

82.El Amari, E.B., et al. Outcome of treated and untreated asymptomatic bacteriuria in renal transplant recipients. Nephrol Dial Transplant, 2011. 26: 4109.

https://www.ncbi.nlm.nih.gov/pubmed/21592976

83.Green, H., et al. Consequences of treated versus untreated asymptomatic bacteriuria in the first year following kidney transplantation: retrospective observational study. Eur J Clin Microbiol Infect Dis, 2013. 32: 127.

https://www.ncbi.nlm.nih.gov/pubmed/22918514

84.Origuen, J., et al. Should Asymptomatic Bacteriuria Be Systematically Treated in Kidney Transplant Recipients? Results From a Randomized Controlled Trial. Am J Transplant, 2016. 16: 2943.

https://www.ncbi.nlm.nih.gov/pubmed/27088545

85.Antonio, M.E.E., et al. Treatment of asymptomatic bacteriuria in the first 2 months after kidney transplant: A controlled clinical trial. Transpl Infect Dis, 2022. 24: e13934.

https://www.ncbi.nlm.nih.gov/pubmed/35980169

86.Sabe, N., et al. Antibiotic Treatment Versus No Treatment for Asymptomatic Bacteriuria in Kidney Transplant Recipients: A Multicenter Randomized Trial. Open Forum Infect Dis, 2019. 6: ofz243.

https://www.ncbi.nlm.nih.gov/pubmed/31214630

87.Arencibia, N., et al. Short-Term Outcome of Untreated Versus Treated Asymptomatic Bacteriuria in Renal Transplant Patients. Transplant Proc, 2016. 48: 2941.

https://www.ncbi.nlm.nih.gov/pubmed/27932112

88.Coussement, J., et al. Antibiotics for asymptomatic bacteriuria in kidney transplant recipients. Cochrane Database Syst Rev, 2018. 2: CD011357.

https://www.ncbi.nlm.nih.gov/pubmed/29390169

89.Gomez-Ochoa, S.A., et al. Systematic review and meta-analysis of asymptomatic bacteriuria after renal transplantation: incidence, risk of complications, and treatment outcomes. Transpl Infect Dis, 2020. 22: e13221.

https://www.ncbi.nlm.nih.gov/pubmed/31782870

90.Nicolle, L.E. Urinary tract infections in patients with spinal injuries. Curr Infect Dis Rep, 2014. 16: 390.

https://www.ncbi.nlm.nih.gov/pubmed/24445675

91.Wullt, B., et al. Bladder, bowel and bugs--bacteriuria in patients with intestinal urinary diversion. World J Urol, 2004. 22: 186.

https://www.ncbi.nlm.nih.gov/pubmed/15309491

92.Qu, L.G., et al. Systematic review: bacterial colonisation of conduits and neobladders-when to test, watch, and treat. World J Urol, 2020. 38: 1413.

https://www.ncbi.nlm.nih.gov/pubmed/31560122

93.Darouiche, R.O., et al. Bacterial interference for prevention of urinary tract infection: a prospective, randomized, placebo-controlled, double-blind pilot trial. Clin Infect Dis, 2005. 41: 1531.

https://www.ncbi.nlm.nih.gov/pubmed/16231269

94.Sunden, F., et al. Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying. J Urol, 2010. 184: 179.

https://www.ncbi.nlm.nih.gov/pubmed/20483149

95.Bonkat, G., et al. Microbial biofilm formation and catheter-associated bacteriuria in patients with suprapubic catheterisation. World J Urol, 2013. 31: 565.

https://www.ncbi.nlm.nih.gov/pubmed/22926265

96.Tenke, P., et al. European and Asian guidelines on management and prevention of catheter-associated urinary tract infections. Int J Antimicrob Agents, 2008. 31 Suppl 1: S68.

https://www.ncbi.nlm.nih.gov/pubmed/18006279

97.Cooper, F.P., et al. Policies for replacing long-term indwelling urinary catheters in adults. Cochrane Database Syst Rev, 2016. 7: CD011115.

https://www.ncbi.nlm.nih.gov/pubmed/27457774

98.Dasgupta, R., et al. Preoperative antibiotics before endourologic surgery: current recommendations. J Endourol, 2009. 23: 1567.

https://www.ncbi.nlm.nih.gov/pubmed/19785548

99.Sobel, J.D., et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis, 2000. 30: 19.

https://www.ncbi.nlm.nih.gov/pubmed/10619727

100.Grabe, M., et al. The effect of a short antibiotic course in transurethral prostatic resection. Scand J Urol Nephrol, 1984. 18: 37.

https://www.ncbi.nlm.nih.gov/pubmed/6202000

101.Grabe, M., et al. Controlled trial of a short and a prolonged course with ciprofloxacin in patients undergoing transurethral prostatic surgery. Eur J Clin Microbiol, 1987. 6: 11.

https://www.ncbi.nlm.nih.gov/pubmed/3569248

102.Cafferkey, M.T., et al. Antibiotics for the prevention of septicaemia in urology. J Antimicrob Chemother, 1982. 9: 471.

https://www.ncbi.nlm.nih.gov/pubmed/7107549

103.Murphy, D.M., et al. Bacteraemia during prostatectomy and other transurethral operations: influence of timing of antibiotic administration. J Clin Pathol, 1984. 37: 673.

https://www.ncbi.nlm.nih.gov/pubmed/6725613

104.Chong, J.T., et al. Pre-procedural antibiotics for endoscopic urological procedures: Initial experience in individuals with spinal cord injury and asymptomatic bacteriuria. J Spinal Cord Med, 2015. 38: 187.

https://www.ncbi.nlm.nih.gov/pubmed/24621035

105.Cordero-Ampuero, J., et al. Are antibiotics necessary in hip arthroplasty with asymptomatic bacteriuria? Seeding risk with/without treatment. Clin Orthop Relat Res, 2013. 471: 3822.

https://www.ncbi.nlm.nih.gov/pubmed/23430723

106.Sousa, R., et al. Is asymptomatic bacteriuria a risk factor for prosthetic joint infection? Clin Infect Dis, 2014. 59: 41.

https://www.ncbi.nlm.nih.gov/pubmed/24723280

107.Rodriguez-Pardo, D., et al. Role of asymptomatic bacteriuria on early periprosthetic joint infection after hip hemiarthroplasty. BARIFER randomized clinical trial. Eur J Clin Microbiol Infect Dis, 2021. 40: 2411.

https://www.ncbi.nlm.nih.gov/pubmed/33864153

108.Gómez-Ochoa, S.A., et al. Risk of Surgical Site Infection in Patients with Asymptomatic Bacteriuria or Abnormal Urinalysis before Joint Arthroplasty: Systematic Review and Meta-Analysis. Surgical Infections, 2019. 20: 159.

https://www.ncbi.nlm.nih.gov/pubmed/30688601

109.Jami, S.A., et al. The necessity of treating asymptomatic bacteriuria with antibiotics in the perioperative period of joint arthroplasty: a metaanalysis. Turk J Med Sci, 2021. 51: 464.

https://www.ncbi.nlm.nih.gov/pubmed/33021755

110.Sousa, R.J.G., et al. Is Routine Urinary Screening Indicated Prior To Elective Total Joint Arthroplasty? A Systematic Review and Meta-Analysis. J Arthroplasty, 2019. 34: 1523.

https://www.ncbi.nlm.nih.gov/pubmed/30956050

111.Wang, C., et al. Current evidence does not support systematic antibiotherapy prior to joint arthroplasty in patients with asymptomatic bacteriuria-a meta analysis. Int Orthop, 2018. 42: 479.

https://www.ncbi.nlm.nih.gov/pubmed/29368046

112.Gomez-Ochoa, S.A., et al. Lack of Benefit on Treating Asymptomatic Bacteriuria Prior to Cardiovascular Surgery: a Systematic Review and Meta-Analysis. Braz J Cardiovasc Surg, 2018. 33: 641.

https://www.ncbi.nlm.nih.gov/pubmed/30652758

113.Foxman, B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon, 2003. 49: 53.

https://www.ncbi.nlm.nih.gov/pubmed/12601337

114.Wagenlehner, F.M., et al. Uncomplicated urinary tract infections. Dtsch Arztebl Int, 2011. 108: 415.

https://www.ncbi.nlm.nih.gov/pubmed/21776311

115.Stamm, W.E., et al. Management of urinary tract infections in adults. N Engl J Med, 1993. 329: 1328.

https://www.ncbi.nlm.nih.gov/pubmed/8413414

116.Foxman, B., et al. Urinary tract infection among women aged 40 to 65: behavioral and sexual risk factors. J Clin Epidemiol, 2001. 54: 710.

https://www.ncbi.nlm.nih.gov/pubmed/11438412

117.van Buul, L.W., et al. The Development of a Decision Tool for the Empiric Treatment of Suspected Urinary Tract Infection in Frail Older Adults: A Delphi Consensus Procedure. J Am Med Dir Assoc, 2018. 19: 757.

https://www.ncbi.nlm.nih.gov/pubmed/29910137

118.Bent, S., et al. Does this woman have an acute uncomplicated urinary tract infection? JAMA, 2002. 287: 2701.

https://www.ncbi.nlm.nih.gov/pubmed/12020306

119.Bradbury, S.M. Collection of urine specimens in general practice: to clean or not to clean? J R Coll Gen Pract, 1988. 38: 363.

https://www.ncbi.nlm.nih.gov/pubmed/3256648

120.Lifshitz, E., et al. Outpatient urine culture: does collection technique matter? Arch Intern Med, 2000. 160: 2537.

https://www.ncbi.nlm.nih.gov/pubmed/10979067

121.Fihn, S.D. Clinical practice. Acute uncomplicated urinary tract infection in women. N Engl J Med, 2003. 349: 259.

https://www.ncbi.nlm.nih.gov/pubmed/12867610

122.Foxman, B., et al. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am, 2003. 17: 227.

https://www.ncbi.nlm.nih.gov/pubmed/12848468

123.Gbinigie, O.A., et al. Cranberry Extract for Symptoms of Acute, Uncomplicated Urinary Tract Infection: A Systematic Review. Antibiotics (Basel), 2020. 10.

https://www.ncbi.nlm.nih.gov/pubmed/33375566

124.Barbosa-Cesnik, C., et al. Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebo-controlled trial. Clin Infect Dis, 2011. 52: 23.

https://www.ncbi.nlm.nih.gov/pubmed/21148516

125.Little, P., et al. Dipsticks and diagnostic algorithms in urinary tract infection: development and validation, randomised trial, economic analysis, observational cohort and qualitative study. Health Technol Assess, 2009. 13: iii.

https://www.ncbi.nlm.nih.gov/pubmed/19364448

126.Sengupta, K., et al. A Randomized, Double Blind, Controlled, Dose Dependent Clinical Trial to Evaluate the Efficacy of a Proanthocyanidin Standardized Whole Cranberry (Vaccinium macrocarpon) Powder on Infections of the Urinary Tract. Curr Bioactive Compounds, 2011. 7: 39.

http://www.eurekaselect.com/article/18604

127.Parazzini, F., et al. Systematic review of the effect of D-mannose with or without other drugs in the treatment of symptoms of urinary tract infections/cystitis (Review). Biomed Rep, 2022. 17: 69.

https://www.ncbi.nlm.nih.gov/pubmed/35815191

128.Rădulescu, D., et al. Combination of cranberry extract and D-mannose - possible enhancer of uropathogen sensitivity to antibiotics in acute therapy of urinary tract infections: Results of a pilot study. Exp Ther Med, 2020. 20: 3399.

https://www.ncbi.nlm.nih.gov/pubmed/32905041

129.Porru, D., et al. Oral D-mannose in recurrent urinary tract infections in women: a pilot study. J Clin Urol, 2014. 7: 208.

https://journals.sagepub.com/doi/10.1177/2051415813518332

130.Domenici, L., et al. D-mannose: a promising support for acute urinary tract infections in women. A pilot study. Eur Rev Med Pharmacol Sci, 2016. 20: 2920.

https://www.ncbi.nlm.nih.gov/pubmed/27424995

131.Salvatore, S., et al. A Randomized Controlled Trial Comparing a New D-Mannose-based Dietary Supplement to Placebo for the Treatment of Uncomplicated Escherichia coli Urinary Tract Infections. Eur Urol Focus, 2023. 9: 654.

https://www.ncbi.nlm.nih.gov/pubmed/36621376

132.Wagenlehner, F.M., et al. Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial. Urol Int, 2018. 101: 327.

https://www.ncbi.nlm.nih.gov/pubmed/30231252

133.Cai, T., et al. L-Methionine associated with Hibiscus sabdariffa and Boswellia serrata extracts are not inferior to antibiotic treatment for symptoms relief in patients affected by recurrent uncomplicated urinary tract infections: Focus on antibiotic-sparing approach. Arch Ital Urol Androl, 2018. 90: 97.

https://www.ncbi.nlm.nih.gov/pubmed/29974725

134.van Wietmarschen, H., et al. Effectiveness of herbal medicines to prevent and control symptoms of urinary tract infections and to reduce antibiotic use: A literature review. Integr Med Res, 2022. 11: 100892.

https://www.ncbi.nlm.nih.gov/pubmed/36345487

135.Costache, R.C., et al. Xyloglucan + Gelose Combination versus Placebo as Adjuvant Therapy to First-Line Antimicrobials for Uncomplicated Urinary Tract Infection in Adults. Urol Int, 2019. 102: 468.

https://www.ncbi.nlm.nih.gov/pubmed/30889607

136.Cai, T., et al. Xyloglucan, Hibiscus and Propolis in the Management of Uncomplicated Lower Urinary Tract Infections: A Systematic Review and Meta-Analysis. Antibiotics (Basel), 2021. 11.

https://www.ncbi.nlm.nih.gov/pubmed/35052890

137.Gupta, V., et al. Effectiveness of Prophylactic Oral and/or Vaginal Probiotic Supplementation in the Prevention of Recurrent Urinary Tract Infections: A Randomized, Double-Blind, Placebo-Controlled Trial. Clin Infect Dis, 2024. 78: 1154.

https://www.ncbi.nlm.nih.gov/pubmed/38084984

138.Kranz, J., et al. Original Article Phytotherapy in Adults With Recurrent Uncomplicated Cystitis. Dtsch Arztebl Int, 2022. 119: 353.

https://www.ncbi.nlm.nih.gov/pubmed/35101170

139.Rondanelli, M., et al. Supplementation with Highly Standardized Cranberry Extract Phytosome Achieved the Modulation of Urinary Tract Infection Episodes in Diabetic Postmenopausal Women Taking SGLT-2 Inhibitors: A RCT Study. Nutrients, 2024. 16.

https://www.ncbi.nlm.nih.gov/pubmed/38999860

140.Tsiakoulias, E., et al. Randomized, placebo-controlled, double-blinded study of prophylactic cranberries use in women with recurrent uncomplicated cystitis. World J Urol, 2024. 42: 27.

https://www.ncbi.nlm.nih.gov/pubmed/38214795

141.Moro, C., et al. Cranberry Juice, Cranberry Tablets, or Liquid Therapies for Urinary Tract Infection: A Systematic Review and Network Meta-analysis. Eur Urol Focus.

https://www.ncbi.nlm.nih.gov/pubmed/39030132

142.Lenger, S.M., et al. D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol, 2020. 223: 265 e1.

https://www.ncbi.nlm.nih.gov/pubmed/32497610

143.Hayward, G., et al. d-Mannose for Prevention of Recurrent Urinary Tract Infection Among Women: A Randomized Clinical Trial. JAMA Int Med, 2024. 184: 619.

https://www.ncbi.nlm.nih.gov/pubmed/38587819

144.Naber, K.G., et al. Therapeutic strategies for uncomplicated cystitis in women. GMS Infect Dis, 2024. 12: Doc01.

https://www.ncbi.nlm.nih.gov/pubmed/38764941

145.Sabadash, M., et al. Canephron® N in the treatment of recurrent cystitis in women of child-bearing Age: a randomised controlled study. Clin Phytosci, 2017. 3: 9.

https://clinphytoscience.springeropen.com/articles/10.1186/s40816-017-0046-7

146.Hudson, R.E., et al. Examination of Complementary Medicine for Treating Urinary Tract Infections Among Pregnant Women and Children. Front Pharmacol, 2022. 13: 883216.

https://www.ncbi.nlm.nih.gov/pubmed/35571128

147.Falagas, M.E., et al. Antibiotics versus placebo in the treatment of women with uncomplicated cystitis: a meta-analysis of randomized controlled trials. J Infect, 2009. 58: 91.

https://www.ncbi.nlm.nih.gov/pubmed/19195714

148.AWMF, unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei Erwachsenen – Aktualisierung 2024. 2024.

https://register.awmf.org/de/leitlinien/detail/043-044

149.Bleidorn, J., et al. Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection? - Results of a randomized controlled pilot trial. BMC Med, 2010. 8: 30.

https://www.ncbi.nlm.nih.gov/pubmed/20504298

150.Gágyor, I., et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ, 2015. 351: h6544.

https://www.ncbi.nlm.nih.gov/pubmed/26698878

151.Vik, I., et al. Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women-A double-blind, randomized non-inferiority trial. PLoS Med, 2018. 15: e1002569.

https://www.ncbi.nlm.nih.gov/pubmed/29763434

152.Kronenberg, A., et al. Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ, 2017. 359: j4784.

https://www.ncbi.nlm.nih.gov/pubmed/29113968

153.Gágyor, I., et al. Herbal treatment with uva ursi extract versus fosfomycin in women with uncomplicated urinary tract infection in primary care: a randomized controlled trial. Clin Microbiol Infect, 2021. 27: 1441.

https://www.ncbi.nlm.nih.gov/pubmed/34111592

154.Kaußner, Y., et al. Reducing antibiotic use in uncomplicated urinary tract infections in adult women: a systematic review and individual participant data meta-analysis. Clin Microbiol Infect, 2022. 28: 1558.

https://www.ncbi.nlm.nih.gov/pubmed/35788049

155.Mann, N.K., et al. Potentially Inadequate Medications in the Elderly: PRISCUS 2.0. Dtsch Arztebl Int, 2023. 120: 3.

https://www.ncbi.nlm.nih.gov/pubmed/36507719

156.Gupta, K., et al. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med, 2007. 167: 2207.

https://www.ncbi.nlm.nih.gov/pubmed/17998493

157.Lecomte, F., et al. Single-dose treatment of cystitis with fosfomycin trometamol (Monuril): analysis of 15 comparative trials on 2,048 patients. Giorn It Ost Gin, 1997. 19: 399.

https://www.sciencedirect.com/science/article/pii/S0399077X96802095

158.Nicolle, L.E. Pivmecillinam in the treatment of urinary tract infections. J Antimicrob Chemother, 2000. 46 Suppl 1: 35.

https://www.ncbi.nlm.nih.gov/pubmed/11051622

159.Huttner, A., et al. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother, 2015. 70: 2456.

https://www.ncbi.nlm.nih.gov/pubmed/26066581

160.Gupta, K., et al. Outcomes associated with trimethoprim/sulphamethoxazole (TMP/SMX) therapy in TMP/SMX resistant community-acquired UTI. Int J Antimicrob Agents, 2002. 19: 554.

https://www.ncbi.nlm.nih.gov/pubmed/12135847

161.Warren, J.W., et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis, 1999. 29: 745.

https://www.ncbi.nlm.nih.gov/pubmed/10589881

162.Hooton, T.M., et al. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. JAMA, 2012. 307: 583.

https://www.ncbi.nlm.nih.gov/pubmed/22318279

163.Hooton, T.M., et al. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA, 2005. 293: 949.

https://www.ncbi.nlm.nih.gov/pubmed/15728165

164.EMA. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. Quinolone and fluoroquinolone Article-31 referral, 2019.

https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products

165.Vazquez, J.C., et al. Treatments for symptomatic urinary tract infections during pregnancy. Cochrane Database Syst Rev, 2000: CD002256.

https://www.ncbi.nlm.nih.gov/pubmed/10908537

166.Geerts, A.F., et al. Ineffectiveness and adverse events of nitrofurantoin in women with urinary tract infection and renal impairment in primary care. Eur J Clin Pharmacol, 2013. 69: 1701.

https://www.ncbi.nlm.nih.gov/pubmed/23660771

167.Wagenlehner, F.M., et al. Antimicrobials in urogenital infections. Int J Antimicrob Agents, 2011. 38 Suppl: 3.

https://www.ncbi.nlm.nih.gov/pubmed/22019184

168.Hooton, T.M. Recurrent urinary tract infection in women. Int J Antimicrob Agents, 2001. 17: 259.

https://www.ncbi.nlm.nih.gov/pubmed/11295405

169.Naber, K.G., et al. Psychosocial burden of recurrent uncomplicated urinary tract infections. GMS Infect Dis, 2022. 10: Doc01.

https://www.ncbi.nlm.nih.gov/pubmed/35463815

170.van Haarst, E.P., et al. Evaluation of the diagnostic workup in young women referred for recurrent lower urinary tract infections. Urology, 2001. 57: 1068.

https://www.ncbi.nlm.nih.gov/pubmed/11377307

171.Hooton, T.M., Prevention of recurrent urogenital tract infections in adult women, in: EAU/International Consultation on Urological Infections. T, K.G. Naber, A.J. Schaeffer, C.F. Hynes et al., Editors. 2010, European Association of Urology: The Netherlands.

http://www.icud.info/urogenitalinfections.html

172.Cai, T., et al. Management of Recurrent Cystitis in Women: When Prompt Identification of Risk Factors Might Make a Difference. Eur Urol Focus, 2022. 8: 1476.

https://www.ncbi.nlm.nih.gov/pubmed/35135727

173.Adatto, K., et al. Behavioral factors and urinary tract infection. JAMA, 1979. 241: 2525.

https://www.ncbi.nlm.nih.gov/pubmed/439337

174.Lumsden, L., et al. Effects of an educational intervention on the rate of recurrent urinary tract infections in selected female outpatients. Women Health, 1985. 10: 79.

https://www.ncbi.nlm.nih.gov/pubmed/3984360

175.Hooton, T.M., et al. Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial. JAMA Intern Med, 2018. 178: 1509.

https://www.ncbi.nlm.nih.gov/pubmed/30285042

176.Chen, Y.Y., et al. Estrogen for the prevention of recurrent urinary tract infections in postmenopausal women: a meta-analysis of randomized controlled trials. Int Urogynecol J, 2021. 32: 17.

https://www.ncbi.nlm.nih.gov/pubmed/32564121

177.Beerepoot, M.A., et al. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J Urol, 2013. 190: 1981.

https://www.ncbi.nlm.nih.gov/pubmed/23867306

178.Leckie, K.J. What is the evidence for the role of oestrogen in the prevention of recurrent urinary tract infections in postmenopausal women? An evidence-based review. J Clin Gerontol Geriatr, 2010. 1: 31.

https://www.sciencedirect.com/science/article/pii/S2210833510000298?via%3Dihub

179.Duenas-Garcia, O.F., et al. Pharmacological Agents to Decrease New Episodes of Recurrent Lower Urinary Tract Infections in Postmenopausal Women. A Systematic Review. Female Pelvic Med Reconstr Surg, 2016. 22: 63.

https://www.ncbi.nlm.nih.gov/pubmed/26825411

180.Pinggera, G.M., et al. Effects of local estrogen therapy on recurrent urinary tract infections in young females under oral contraceptives. Eur Urol, 2005. 47: 243.

https://www.ncbi.nlm.nih.gov/pubmed/15661421

181.Mak, Q., et al. Bacterial Vaccines for the Management of Recurrent Urinary Tract Infections: A Systematic Review and Meta-analysis. Eur Urol Focus, 2024. 10: 761.

https://www.ncbi.nlm.nih.gov/pubmed/38644097

182.Kranz, J., et al. Current Evidence on Nonantibiotic Prevention of Recurrent Urinary Tract Infections. Eur Urol Focus, 2019. 5: 17.

https://www.ncbi.nlm.nih.gov/pubmed/30292420

183.Abad, C.L., et al. The role of lactobacillus probiotics in the treatment or prevention of urogenital infections--a systematic review. J Chemother, 2009. 21: 243.

https://www.ncbi.nlm.nih.gov/pubmed/19567343

184.Canales, J., et al. Are probiotics effective in preventing urinary tract infection? Medwave, 2018. 18: e7186.

https://www.ncbi.nlm.nih.gov/pubmed/29624569

185.Falagas, M.E., et al. Probiotics for prevention of recurrent urinary tract infections in women: a review of the evidence from microbiological and clinical studies. Drugs, 2006. 66: 1253.

https://www.ncbi.nlm.nih.gov/pubmed/16827601

186.Grin, P.M., et al. Lactobacillus for preventing recurrent urinary tract infections in women: meta-analysis. Can J Urol, 2013. 20: 6607.

https://www.ncbi.nlm.nih.gov/pubmed/23433130

187.Hanson, L., et al. Probiotics for Treatment and Prevention of Urogenital Infections in Women: A Systematic Review. J Midwifery Womens Health, 2016. 61: 339.

https://www.ncbi.nlm.nih.gov/pubmed/27218592

188.Ng, Q.X., et al. Use of Lactobacillus spp. to prevent recurrent urinary tract infections in females. Med Hypotheses, 2018. 114: 49.

https://www.ncbi.nlm.nih.gov/pubmed/29602464

189.Akgul, T., et al. The role of probiotics in women with recurrent urinary tract infections. Turk J Urol, 2018. 44: 377.

https://www.ncbi.nlm.nih.gov/pubmed/30487041

190.Andreu, A. Lactobacillus as a probiotic for preventing urogenital infections. Rev Med Microbiol, 2004. 15: 1.

https://www.researchgate.net/publication/232117977

191.Barrons, R., et al. Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review. Clin Ther, 2008. 30: 453.

https://www.ncbi.nlm.nih.gov/pubmed/18405785

192.Hoesl, C.E., et al. The probiotic approach: an alternative treatment option in urology. Eur Urol, 2005. 47: 288.

https://www.ncbi.nlm.nih.gov/pubmed/15716188

193.Ray, K. Infection: Lactobacillus probiotic could prevent recurrent UTI. Nat Rev Urol, 2011. 8: 292.

https://www.ncbi.nlm.nih.gov/pubmed/21660070

194.Reid, G., et al. Probiotics to prevent urinary tract infections: the rationale and evidence. World J Urol, 2006. 24: 28.

https://www.ncbi.nlm.nih.gov/pubmed/16389539

195.Abdullatif, V.A., et al. Efficacy of Probiotics as Prophylaxis for Urinary Tract Infections in Premenopausal Women: A Systematic Review and Meta-Analysis. Cureus, 2021. 13: e18843.

https://www.ncbi.nlm.nih.gov/pubmed/34671514

196.Jepson, R.G., et al. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev, 2012. 10: CD001321.

https://www.ncbi.nlm.nih.gov/pubmed/23076891

197.Fu, Z., et al. Cranberry Reduces the Risk of Urinary Tract Infection Recurrence in Otherwise Healthy Women: A Systematic Review and Meta-Analysis. J Nutr, 2017. 147: 2282.

https://www.ncbi.nlm.nih.gov/pubmed/29046404

198.Luis, A., et al. Can Cranberries Contribute to Reduce the Incidence of Urinary Tract Infections? A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Clinical Trials. J Urol, 2017. 198: 614.

https://www.ncbi.nlm.nih.gov/pubmed/28288837

199.Wang, C.H., et al. Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med, 2012. 172: 988.

https://www.ncbi.nlm.nih.gov/pubmed/22777630

200.Tambunan, M.P., et al. Cranberries for women with recurrent urinary tract infection: a meta-analysis. Med J Indonesia, 2019. 28: 268.

https://mji.ui.ac.id/journal/index.php/mji/article/view/3299

201.Xia, J.Y., et al. Consumption of cranberry as adjuvant therapy for urinary tract infections in susceptible populations: A systematic review and meta-analysis with trial sequential analysis. PLoS One, 2021. 16: e0256992.

https://www.ncbi.nlm.nih.gov/pubmed/34473789

202.Liska, D.J., et al. Cranberries and Urinary Tract Infections: How Can the Same Evidence Lead to Conflicting Advice? Adv Nutr, 2016. 7: 498.

https://www.ncbi.nlm.nih.gov/pubmed/27184277

203.Babar, A., et al. High dose versus low dose standardized cranberry proanthocyanidin extract for the prevention of recurrent urinary tract infection in healthy women: a double-blind randomized controlled trial. BMC Urol, 2021. 21: 44.

https://www.ncbi.nlm.nih.gov/pubmed/33757474

204.Kyriakides, R., et al. Role of D-Mannose in the Prevention of Recurrent Urinary Tract Infections: Evidence from a Systematic Review of the Literature. Eur Urol Focus, 2021. 7: 1166.

https://www.ncbi.nlm.nih.gov/pubmed/32972899

205.Cooper, T.E., et al. D-mannose for preventing and treating urinary tract infections. Cochrane Database Syst Rev, 2022. 8: CD013608.

https://www.ncbi.nlm.nih.gov/pubmed/36041061

206.Damiano, R., et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol, 2011. 59: 645.

https://www.ncbi.nlm.nih.gov/pubmed/21272992

207.De Vita, D., et al. Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study. Int Urogynecol J, 2012. 23: 1707.

https://www.ncbi.nlm.nih.gov/pubmed/22614285

208.Goddard, J.C., et al. Intravesical hyaluronic acid and chondroitin sulfate for recurrent urinary tract infections: systematic review and meta-analysis. Int Urogynecol J, 2018. 29: 933.

https://www.ncbi.nlm.nih.gov/pubmed/29181550

209.Lee, B.S., et al. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev, 2012. 10: CD003265.

https://www.ncbi.nlm.nih.gov/pubmed/23076896

210.Bakhit, M., et al. Use of methenamine hippurate to prevent urinary tract infections in community adult women: a systematic review and meta-analysis. Br J Gen Pract, 2021. 71: e528.

https://www.ncbi.nlm.nih.gov/pubmed/34001538

211.Harding, C., et al. Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT. Health Technol Assess, 2022. 26: 1.

https://www.ncbi.nlm.nih.gov/pubmed/35535708

212.Harding, C., et al. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial. BMJ, 2022. 376: e068229.

https://www.ncbi.nlm.nih.gov/pubmed/35264408

213.Nalliah, S., et al. The use of chemotherapeutic agents as prophylaxis for recurrent urinary tract infection in healthy nonpregnant women: A network meta-analysis. Indian J Urol, 2019. 35: 147.

https://www.ncbi.nlm.nih.gov/pubmed/31000921

214.Ahmed, H., et al. Long-term antibiotics for prevention of recurrent urinary tract infection in older adults: systematic review and meta-analysis of randomised trials. BMJ Open, 2017. 7: e015233.

https://www.ncbi.nlm.nih.gov/pubmed/28554926

215.Price, J.R., et al. Nitrofurantoin vs other prophylactic agents in reducing recurrent urinary tract infections in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol, 2016. 215: 548.

https://www.ncbi.nlm.nih.gov/pubmed/27457111

216.Albert, X., et al. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev, 2004. 2004: CD001209.

https://www.ncbi.nlm.nih.gov/pubmed/15266443

217.Eells, S.J., et al. Recurrent urinary tract infections among women: comparative effectiveness of 5 prevention and management strategies using a Markov chain Monte Carlo model. Clin Infect Dis, 2014. 58: 147.

https://www.ncbi.nlm.nih.gov/pubmed/24065333

218.Anger, J., et al. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. J Urol, 2019. 202: 282.

https://www.ncbi.nlm.nih.gov/pubmed/31042112

219.Kranz, J., et al. The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention. Urol Int, 2018. 100: 271.

https://www.ncbi.nlm.nih.gov/pubmed/29539622

220.Epp, A., et al. No. 250-Recurrent Urinary Tract Infection. J Obstet Gynaecol Can, 2017. 39: e422.

https://www.ncbi.nlm.nih.gov/pubmed/28935065

221.Lichtenberger, P., et al. Antimicrobial prophylaxis in women with recurrent urinary tract infections. Int J Antimicrob Agents, 2011. 38 Suppl: 36.

https://www.ncbi.nlm.nih.gov/pubmed/22055655

222.Sen, A. Recurrent cystitis in non-pregnant women. BMJ Clin Evid, 2008. 2008.

https://www.ncbi.nlm.nih.gov/pubmed/19445741

223.Chew, L.D., et al. Recurrent cystitis in nonpregnant women. West J Med, 1999. 170: 274.

https://www.ncbi.nlm.nih.gov/pubmed/10379218

224.Rudenko, N., et al. Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo controlled study. Arzneimittelforschung, 2005. 55: 420.

https://www.ncbi.nlm.nih.gov/pubmed/16080282

225.Costantini, E., et al. Prulifloxacin vs fosfomycin for prophylaxis in female patients with recurrent UTIs: a non-inferiority trial. Int Urogynecol J, 2014. 25: 1173.

https://www.ncbi.nlm.nih.gov/pubmed/24554302

226.Pfau, A., et al. Effective prophylaxis for recurrent urinary tract infections during pregnancy. Clin Infect Dis, 1992. 14: 810.

https://www.ncbi.nlm.nih.gov/pubmed/1576275

227.Schaeffer, A.J., et al. Efficacy and safety of self-start therapy in women with recurrent urinary tract infections. J Urol, 1999. 161: 207.

https://www.ncbi.nlm.nih.gov/pubmed/10037399

228.Scholes, D., et al. Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med, 2005. 142: 20.

https://www.ncbi.nlm.nih.gov/pubmed/15630106

229.Hill, J.B., et al. Acute pyelonephritis in pregnancy. Obstet Gynecol, 2005. 105: 18.

https://www.ncbi.nlm.nih.gov/pubmed/15625136

230.Fulop, T. Acute Pyelonephritis Workup. 2012.

http://emedicine.medscape.com/article/245559-workup#aw2aab6b5b3

231.van Nieuwkoop, C., et al. Predicting the need for radiologic imaging in adults with febrile urinary tract infection. Clin Infect Dis, 2010. 51: 1266.

https://www.ncbi.nlm.nih.gov/pubmed/21034195

232.Cattrall, J.W.S., et al. A systematic review of randomised clinical trials for oral antibiotic treatment of acute pyelonephritis. Eur J Clin Microbiol Infect Dis, 2018. 37: 2285.

https://www.ncbi.nlm.nih.gov/pubmed/30191339

233.Gupta, K., et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis, 2011. 52: e103.

https://www.ncbi.nlm.nih.gov/pubmed/21292654

234.Berti, F., et al. Short versus long course antibiotic therapy for acute pyelonephritis in adults: a systematic review and meta-analysis. Ital J Med, 2018. 12: 39.

https://www.italjmed.org/index.php/ijm/article/view/itjm.2018.840

235.Hooton, T.M. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med, 2012. 366: 1028.

https://www.ncbi.nlm.nih.gov/pubmed/22417256

236.Arakawa, S., et al. The efficacy and safety of tazobactam/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection. J Infect Chemother, 2019. 25: 104.

https://www.ncbi.nlm.nih.gov/pubmed/30420153

237.Armstrong, E.S., et al. Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections. BMC Infect Dis, 2016. 16: 710.

https://www.ncbi.nlm.nih.gov/pubmed/27887579

238.Huntington, J.A., et al. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial. J Antimicrob Chemother, 2016. 71: 2014.

https://www.ncbi.nlm.nih.gov/pubmed/26994090

239.Carmeli, Y., et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis, 2016. 16: 661.

https://www.ncbi.nlm.nih.gov/pubmed/27107460

240.Sims, M., et al. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother, 2017. 72: 2616.

https://www.ncbi.nlm.nih.gov/pubmed/28575389

241.Wagenlehner, F.M., et al. Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clin Infect Dis, 2016. 63: 754.

https://www.ncbi.nlm.nih.gov/pubmed/27313268

242.Kaye, K.S., et al. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. JAMA, 2018. 319: 788.

https://www.ncbi.nlm.nih.gov/pubmed/29486041

243.Wunderink, R.G., et al. Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. Infect Dis Ther, 2018. 7: 439.

https://www.ncbi.nlm.nih.gov/pubmed/30270406

244.Wagenlehner, F.M.E., et al. Once-Daily Plazomicin for Complicated Urinary Tract Infections. N Engl J Med, 2019. 380: 729.

https://www.ncbi.nlm.nih.gov/pubmed/30786187

245.Portsmouth, S., et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis, 2018. 18: 1319.

https://www.ncbi.nlm.nih.gov/pubmed/30509675

246.Pitout, J.D. Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs, 2010. 70: 313.

https://www.ncbi.nlm.nih.gov/pubmed/20166768

247.Mombelli, G., et al. Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial. Arch Intern Med, 1999. 159: 53.

https://www.ncbi.nlm.nih.gov/pubmed/9892331

248.Millar, L.K., et al. Outpatient treatment of pyelonephritis in pregnancy: a randomized controlled trial. Obstet Gynecol, 1995. 86: 560.

https://www.ncbi.nlm.nih.gov/pubmed/7675380

249.Wing, D.A., et al. A randomized trial of three antibiotic regimens for the treatment of pyelonephritis in pregnancy. Obstet Gynecol, 1998. 92: 249.

https://www.ncbi.nlm.nih.gov/pubmed/9699761

250.Ulleryd, P., et al. Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up. Scand J Infect Dis, 2003. 35: 34.

https://www.ncbi.nlm.nih.gov/pubmed/12685882

251.Chihara, S., et al. Staphylococcus aureus bacteriuria as a prognosticator for outcome of Staphylococcus aureus bacteremia: a case-control study. BMC Infect Dis, 2010. 10: 225.

https://www.ncbi.nlm.nih.gov/pubmed/20667139

252.Papadimitriou-Olivgeris, M., et al. Clinical significance of concomitant bacteriuria in patients with Staphylococcus aureus bacteraemia. Eur J Clin Microbiol Infect Dis, 2023. 42: 379.

https://www.ncbi.nlm.nih.gov/pubmed/36725816

253.Kawashima, A., et al. Radiologic evaluation of patients with renal infections. Infect Dis Clin North Am, 2003. 17: 433.

https://www.ncbi.nlm.nih.gov/pubmed/12848478

254.Zulfiqar, M., et al. Imaging of Renal Infections and Inflammatory Disease. Radiol Clin North Am, 2020. 58: 909.

https://www.ncbi.nlm.nih.gov/pubmed/32792123

255.Golan, Y. Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options. BMC Infect Dis, 2015. 15: 313.

https://www.ncbi.nlm.nih.gov/pubmed/26243291

256.Singh, K.P., et al. Systematic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection. Antimicrob Agents Chemother, 2013. 57: 5284.

https://www.ncbi.nlm.nih.gov/pubmed/23939900

257.Kaye, K.S., et al. Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial. Clin Infect Dis, 2019. 69: 2045.

https://www.ncbi.nlm.nih.gov/pubmed/30861061

258.Wagenlehner, F.M.E., et al. Once-Daily Plazomicin for Complicated Urinary Tract Infections. N Engl J Med, 2019. 380: 729.

https://www.ncbi.nlm.nih.gov/pubmed/30786187

259.Popejoy, M.W., et al. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials. J Antimicrob Chemother, 2017. 72: 268.

https://www.ncbi.nlm.nih.gov/pubmed/27707990

260.Daneman, N., et al. Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections. N Engl J Med, 2024.

https://www.ncbi.nlm.nih.gov/pubmed/39565030

261.McAteer, J., et al. Defining the Optimal Duration of Therapy for Hospitalized Patients With Complicated Urinary Tract Infections and Associated Bacteremia. Clin Infect Dis, 2023. 76: 1604.

https://www.ncbi.nlm.nih.gov/pubmed/36633559

262.Peterson, J., et al. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology, 2008. 71: 17.

https://www.ncbi.nlm.nih.gov/pubmed/18242357

263.Sandberg, T., et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet, 2012. 380: 484.

https://www.ncbi.nlm.nih.gov/pubmed/22726802

264.van Nieuwkoop, C., et al. Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women. BMC Med, 2017. 15: 70.

https://www.ncbi.nlm.nih.gov/pubmed/28366170

265.Lafaurie, M., et al. Antimicrobial for 7 or 14 Days for Febrile Urinary Tract Infection in Men: A Multicenter Noninferiority Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Clin Infect Dis, 2023. 76: 2154.

https://www.ncbi.nlm.nih.gov/pubmed/36785526

266.Erba, L., et al. Short vs long-course antibiotic therapy in pyelonephritis: a comparison of systematic reviews and guidelines for the SIMI choosing wisely campaign. Intern Emerg Med, 2021. 16: 313.

https://www.ncbi.nlm.nih.gov/pubmed/32566969

267.Nicolle, L.E. A practical guide to the management of complicated urinary tract infection. Drugs, 1997. 53: 583.

https://www.ncbi.nlm.nih.gov/pubmed/9098661

268.Gould, C.V., et al. Guideline for prevention of catheter-associated urinary tract infections 2009. Infect Control Hosp Epidemiol, 2010. 31: 319.

https://www.ncbi.nlm.nih.gov/pubmed/20156062

269.Magill, S.S., et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med, 2014. 370: 1198.

https://www.ncbi.nlm.nih.gov/pubmed/24670166

270.Garibaldi, R.A., et al. Factors predisposing to bacteriuria during indwelling urethral catheterization. N Engl J Med, 1974. 291: 215.

https://www.ncbi.nlm.nih.gov/pubmed/4834750

271.Kunin, C.M., et al. Prevention of catheter-induced urinary-tract infections by sterile closed drainage. N Engl J Med, 1966. 274: 1155.

https://www.ncbi.nlm.nih.gov/pubmed/5934951

272.Hartstein, A.I., et al. Nosocomial urinary tract infection: a prospective evaluation of 108 catheterized patients. Infect Control, 1981. 2: 380.

https://www.ncbi.nlm.nih.gov/pubmed/6795141

273.Warren, J.W., et al. Fever, bacteremia, and death as complications of bacteriuria in women with long-term urethral catheters. J Infect Dis, 1987. 155: 1151.

https://www.ncbi.nlm.nih.gov/pubmed/3572035

274.Classen, D.C., et al. Prevention of catheter-associated bacteriuria: clinical trial of methods to block three known pathways of infection. Am J Infect Control, 1991. 19: 136.

https://www.ncbi.nlm.nih.gov/pubmed/1863002

275.Saint, S., et al. Preventing catheter-related bacteriuria: should we? Can we? How? Arch Intern Med, 1999. 159: 800.

https://www.ncbi.nlm.nih.gov/pubmed/10219925

276.Maki, D.G., et al. Engineering out the risk for infection with urinary catheters. Emerg Infect Dis, 2001. 7: 342.

https://www.ncbi.nlm.nih.gov/pubmed/11294737

277.Li, F., et al. Risk factors for catheter-associated urinary tract infection among hospitalized patients: A systematic review and meta-analysis of observational studies. J Adv Nurs, 2019. 75: 517.

https://www.ncbi.nlm.nih.gov/pubmed/30259542

278.Jacobsen, S.M., et al. Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin Microbiol Rev, 2008. 21: 26.

https://www.ncbi.nlm.nih.gov/pubmed/18202436

279.Geerlings, S.E., et al. SWAB Guidelines for Antimicrobial Therapy of Complicated Urinary Tract Infections in Adults. SWAB Guidelines, 2013.

https://swab.nl/exec/file/download/84

280.Durant, D.J. Nurse-driven protocols and the prevention of catheter-associated urinary tract infections: A systematic review. Am J Infect Control, 2017. 45: 1331.

https://www.ncbi.nlm.nih.gov/pubmed/28982611

281.Mody, L., et al. A targeted infection prevention intervention in nursing home residents with indwelling devices: a randomized clinical trial. JAMA Intern Med, 2015. 175: 714.

https://www.ncbi.nlm.nih.gov/pubmed/25775048

282.Meddings, J., et al. Systematic Review of Interventions to Reduce Urinary Tract Infection in Nursing Home Residents. J Hosp Med, 2017. 12: 356.

https://www.ncbi.nlm.nih.gov/pubmed/28459908

283.Kachare, S.D., et al. Toward eliminating catheter-associated urinary tract infections in an academic health center. J Surg Res, 2014. 192: 280.

https://www.ncbi.nlm.nih.gov/pubmed/25150082

284.Cao, Y., et al. Comparison of the preventive effect of urethral cleaning versus disinfection for catheter-associated urinary tract infections in adults: A network meta-analysis. Int J Infect Dis, 2018. 76: 102.

https://www.ncbi.nlm.nih.gov/pubmed/30243912

285.Noto, M.J., et al. Chlorhexidine bathing and health care-associated infections: a randomized clinical trial. JAMA, 2015. 313: 369.

https://www.ncbi.nlm.nih.gov/pubmed/25602496

286.Huang, H.P., et al. The efficacy of daily chlorhexidine bathing for preventing healthcare-associated infections in adult intensive care units. Korean J Intern Med, 2016. 31: 1159.

https://www.ncbi.nlm.nih.gov/pubmed/27048258

287.Li, M., et al. The effect of bladder catheterization on the incidence of urinary tract infection in laboring women with epidural analgesia: a meta-analysis of randomized controlled trials. Int Urogynecol J, 2019. 30: 1419.

https://www.ncbi.nlm.nih.gov/pubmed/30834958

288.Gibson, K.E., et al. Indwelling urethral versus suprapubic catheters in nursing home residents: determining the safest option for long-term use. J Hosp Infect, 2019. 102: 219.

https://www.ncbi.nlm.nih.gov/pubmed/30056015

289.Kidd, E.A., et al. Urethral (indwelling or intermittent) or suprapubic routes for short-term catheterisation in hospitalised adults. Cochrane Database Syst Rev, 2015. 2015: CD004203.

https://www.ncbi.nlm.nih.gov/pubmed/26661940

290.Jamison, J., et al. Catheter policies for management of long term voiding problems in adults with neurogenic bladder disorders. Cochrane Database Syst Rev, 2013. 18: CD004375.

https://www.ncbi.nlm.nih.gov/pubmed/24249436

291.Kranz, J., et al. Catheter-Associated Urinary Tract Infections in Adult Patients. Dtsch Arztebl Int, 2020. 117: 83.

https://www.ncbi.nlm.nih.gov/pubmed/32102727

292.Rognoni, C., et al. Intermittent catheterisation with hydrophilic and non-hydrophilic urinary catheters: systematic literature review and meta-analyses. BMC Urol, 2017. 17: 4.

https://www.ncbi.nlm.nih.gov/pubmed/28073354

293.Tradewell, M., et al. Systematic review and practice policy statements on urinary tract infection prevention in adults with spina bifida. Transl Androl Urol, 2018. 7: S205.

https://www.ncbi.nlm.nih.gov/pubmed/29928619

294.Akcam, F.Z., et al. An investigation of the effectiveness against bacteriuria of silver-coated catheters in short-term urinary catheter applications: A randomized controlled study. J Infect Chemother, 2019. 25: 797.

https://www.ncbi.nlm.nih.gov/pubmed/31030965

295.Singh, R., et al. Randomized controlled trial of silver-alloy-impregnated suprapubic catheters versus standard suprapubic catheters in assessing urinary tract infection rates in urogynecology patients. Int Urogynecol J, 2019. 30: 779.

https://www.ncbi.nlm.nih.gov/pubmed/30145671

296.Lam, T.B., et al. Types of indwelling urethral catheters for short-term catheterisation in hospitalised adults. Cochrane Database Syst Rev, 2014. 2014: CD004013.

https://www.ncbi.nlm.nih.gov/pubmed/25248140

297.Menezes, F.G., et al. A randomized clinical trial comparing Nitrofurazone-coated and uncoated urinary catheters in kidney transplant recipients: Results from a pilot study. Transpl Infect Dis, 2019. 21: e13031.

https://www.ncbi.nlm.nih.gov/pubmed/30451342

298.Bonfill, X., et al. Efficacy and safety of urinary catheters with silver alloy coating in patients with spinal cord injury: a multicentric pragmatic randomized controlled trial. The ESCALE trial. Spine J, 2017. 17: 1650.

https://www.ncbi.nlm.nih.gov/pubmed/28578163

299.Lusardi, G., et al. Antibiotic prophylaxis for short-term catheter bladder drainage in adults. Cochrane Database Syst Rev, 2013. 2013: CD005428.

https://www.ncbi.nlm.nih.gov/pubmed/23824735

300.Pickard, R., et al. Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: the AnTIC RCT. Health Technol Assess, 2018. 22: 1.

https://www.ncbi.nlm.nih.gov/pubmed/29766842

301.Cek, M., et al. Healthcare-associated urinary tract infections in hospitalized urological patients--a global perspective: results from the GPIU studies 2003-2010. World J Urol, 2014. 32: 1587.

https://www.ncbi.nlm.nih.gov/pubmed/24452449

302.Darouiche, R.O., et al. Short versus long course of antibiotics for catheter-associated urinary tract infections in patients with spinal cord injury: a randomized controlled noninferiority trial. Arch Phys Med Rehabil, 2014. 95: 290.

https://www.ncbi.nlm.nih.gov/pubmed/24035770

303.Saint, S., et al. Preventing Catheter-Associated Urinary Tract Infections. N Engl J Med, 2016. 375: 1298.

https://www.ncbi.nlm.nih.gov/pubmed/27682041

304.Bone, R.C., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest, 1992. 101: 1644.

https://www.ncbi.nlm.nih.gov/pubmed/1303622

305.Levy, M.M., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med, 2003. 31: 1250.

https://www.ncbi.nlm.nih.gov/pubmed/12682500

306.Singer, M., et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 2016. 315: 801.

https://www.ncbi.nlm.nih.gov/pubmed/26903338

307.Dellinger, R.P., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med, 2013. 39: 165.

https://www.ncbi.nlm.nih.gov/pubmed/23361625

308.Martin, G.S., et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med, 2003. 348: 1546.

https://www.ncbi.nlm.nih.gov/pubmed/12700374

309.Hotchkiss, R.S., et al. The pathophysiology and treatment of sepsis. N Engl J Med, 2003. 348: 138.

https://www.ncbi.nlm.nih.gov/pubmed/12519925

310.Rosser, C.J., et al. Urinary tract infections in the critically ill patient with a urinary catheter. Am J Surg, 1999. 177: 287.

https://www.ncbi.nlm.nih.gov/pubmed/10326844

311.Brun-Buisson, C., et al. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med, 2004. 30: 580.

https://www.ncbi.nlm.nih.gov/pubmed/14997295

312.Tandogdu, Z., et al. Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003-2013. World J Urol, 2016. 34: 1193.

https://www.ncbi.nlm.nih.gov/pubmed/26658886

313.Wilson, M.L., et al. Principles and rocedures for blood cultures; Approved Guideline. Clinical and Laboratory Standards Institute, 2007.

https://clsi.org/media/1448/m47a_sample.pdf

314.Howell, M.D., et al. Management of Sepsis and Septic Shock. JAMA, 2017. 317: 847.

https://www.ncbi.nlm.nih.gov/pubmed/28114603

315.Brunkhorst, F.M., et al. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med, 2000. 26 Suppl 2: S148.

https://www.ncbi.nlm.nih.gov/pubmed/18470710

316.Angeletti, S., et al. Procalcitonin, MR-Proadrenomedullin, and Cytokines Measurement in Sepsis Diagnosis: Advantages from Test Combination. Dis Markers, 2015. 2015: 951532.

https://www.ncbi.nlm.nih.gov/pubmed/26635427

317.Harbarth, S., et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med, 2001. 164: 396.

https://www.ncbi.nlm.nih.gov/pubmed/11500339

318.Mikkelsen, M.E., et al. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Crit Care Med, 2009. 37: 1670.

https://www.ncbi.nlm.nih.gov/pubmed/19325467

319.Carlet, J., et al. Guideliness for prevention of nosocomial infections in intensive care unit. Arnette Ed Paris 1994: 41. [No abstract available].

320.Riedl, C.R., et al. Bacterial colonization of ureteral stents. Eur Urol, 1999. 36: 53.

https://www.ncbi.nlm.nih.gov/pubmed/10364656

321.DeGroot-Kosolcharoen, J., et al. Evaluation of a urinary catheter with a preconnected closed drainage bag. Infect Control Hosp Epidemiol, 1988. 9: 72.

https://www.ncbi.nlm.nih.gov/pubmed/3343502

322.Rivers, E., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med, 2001. 345: 1368.

https://www.ncbi.nlm.nih.gov/pubmed/11794169

323.Mouncey, P.R., et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med, 2015. 372: 1301.

https://www.ncbi.nlm.nih.gov/pubmed/25776532

324.Investigators, A., et al. Goal-directed resuscitation for patients with early septic shock. N Engl J Med, 2014. 371: 1496.

https://www.ncbi.nlm.nih.gov/pubmed/25272316

325.Pro, C.I., et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med, 2014. 370: 1683.

https://www.ncbi.nlm.nih.gov/pubmed/24635773

326.Investigators, P., et al. Early, Goal-Directed Therapy for Septic Shock - A Patient-Level Meta-Analysis. N Engl J Med, 2017. 376: 2223.

https://www.ncbi.nlm.nih.gov/pubmed/28320242

327.Monnet, X., et al. Prediction of fluid responsiveness: an update. Ann Intensive Care, 2016. 6: 111.

https://www.ncbi.nlm.nih.gov/pubmed/27858374

328.Dellinger, R.P., et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med, 2004. 32: 858.

https://www.ncbi.nlm.nih.gov/pubmed/15090974

329.(AWMF), S3-Leitlinie Urethritis: Management der Urethritis bei männlichen* Jugendlichen und Erwachsenen. 2024.

https://register.awmf.org/assets/guidelines/013-099m_S3_KF_Management-Urethritis-maennliche-Jugendliche-Erwachsenen-MUM___2024-08.pdf

330.Zhang, N., et al. Are Ureaplasma spp. a cause of nongonococcal urethritis? A systematic review and meta-analysis. PLoS One, 2014. 9: e113771.

https://www.ncbi.nlm.nih.gov/pubmed/25463970

331.Horner, P.J., et al. 2016 European guideline on the management of non-gonococcal urethritis. Int J STD AIDS, 2016. 27: 928.

https://www.ncbi.nlm.nih.gov/pubmed/27147267

332.Workowski, K.A., et al. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep, 2015. 64: 1.

https://www.ncbi.nlm.nih.gov/pubmed/26042815

333.Rietmeijer, C.A., et al. Recalibrating the Gram stain diagnosis of male urethritis in the era of nucleic acid amplification testing. Sex Transm Dis, 2012. 39: 18.

https://www.ncbi.nlm.nih.gov/pubmed/22183839

334.Couldwell, D.L., et al. Ureaplasma urealyticum is significantly associated with non-gonococcal urethritis in heterosexual Sydney men. Int J STD AIDS, 2010. 21: 337.

https://www.ncbi.nlm.nih.gov/pubmed/20498103

335.Berntsson, M., et al. Viral and bacterial aetiologies of male urethritis: findings of a high prevalence of Epstein-Barr virus. Int J STD AIDS, 2010. 21: 191.

https://www.ncbi.nlm.nih.gov/pubmed/20215624

336.Sarier, M., et al. Microscopy of Gram-stained urethral smear in the diagnosis of urethritis: Which threshold value should be selected? Andrologia, 2018. 50: e13143.

https://www.ncbi.nlm.nih.gov/pubmed/30238498

337.Moi, H., et al. Microscopy of Stained Urethral Smear in Male Urethritis; Which Cutoff Should be Used? Sex Transm Dis, 2017. 44: 189.

https://www.ncbi.nlm.nih.gov/pubmed/28178118

338.Mensforth, S., et al. Auditing the use and assessing the clinical utility of microscopy as a point-of-care test for Neisseria gonorrhoeae in a Sexual Health clinic. Int J STD AIDS, 2018. 29: 157.

https://www.ncbi.nlm.nih.gov/pubmed/28705094

339.Atkinson, L.M., et al. ‘The waiting game’: are current chlamydia and gonorrhoea near-patient/point-of-care tests acceptable to service users and will they impact on treatment? Int J STD AIDS, 2016. 27: 650.

https://www.ncbi.nlm.nih.gov/pubmed/26092579

340.Harding-Esch, E.M., et al. Impact of deploying multiple point-of-care tests with a ‘sample first’ approach on a sexual health clinical care pathway. A service evaluation. Sex Transm Infect, 2017. 93: 424.

https://www.ncbi.nlm.nih.gov/pubmed/28159916

341.Jensen, J.S., et al. 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol, 2016. 30: 1650.

https://www.ncbi.nlm.nih.gov/pubmed/27505296

342.Centers for Disease, C., et al. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae--2014. MMWR Recomm Rep, 2014. 63: 1.

https://www.ncbi.nlm.nih.gov/pubmed/24622331

343.Miller, J.M., et al. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis, 2018. 67: e1.

https://www.ncbi.nlm.nih.gov/pubmed/29955859

344.Sena, A.C., et al. Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations. Expert Rev Anti Infect Ther, 2014. 12: 673.

https://www.ncbi.nlm.nih.gov/pubmed/24555561

345.Falk, L., et al. Time to eradication of Mycoplasma genitalium after antibiotic treatment in men and women. J Antimicrob Chemother, 2015. 70: 3134.

https://www.ncbi.nlm.nih.gov/pubmed/26283670

346.Ong, J.J., et al. Should Female Partners of Men With Non-Gonococcal Urethritis, Negative for Chlamydia trachomatis and Mycoplasma genitalium, Be Informed and Treated? Clinical Outcomes From a Partner Study of Heterosexual Men With NGU. Sex Transm Dis, 2017. 44: 126.

https://www.ncbi.nlm.nih.gov/pubmed/28079749

347.Kirkcaldy, R.D., et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis, 2014. 59: 1083.

https://www.ncbi.nlm.nih.gov/pubmed/25031289

348.Hathorn, E., et al. The effectiveness of gentamicin in the treatment of Neisseria gonorrhoeae: a systematic review. Syst Rev, 2014. 3: 104.

https://www.ncbi.nlm.nih.gov/pubmed/25239090

349.Soda, M., et al. Evaluation of the Microbiological Efficacy of a Single 2-Gram Dose of Extended-Release Azithromycin by Population Pharmacokinetics and Simulation in Japanese Patients with Gonococcal Urethritis. Antimicrob Agents Chemother, 2018. 62: e01409.

https://www.ncbi.nlm.nih.gov/pubmed/29038284

350.Takahashi, S., et al. Clinical Efficacy of a Single Two Gram Dose of Azithromycin Extended Release for Male Patients with Urethritis. Antibiotics (Basel), 2014. 3: 109.

https://www.ncbi.nlm.nih.gov/pubmed/27025738

351.Yasuda, M., et al. A single 2 g oral dose of extended-release azithromycin for treatment of gonococcal urethritis. J Antimicrob Chemother, 2014. 69: 3116.

https://www.ncbi.nlm.nih.gov/pubmed/24948703

352.Kojima, M., et al. Single-dose treatment of male patients with gonococcal urethritis using 2g spectinomycin: microbiological and clinical evaluations. Int J Antimicrob Agents, 2008. 32: 50.

https://www.ncbi.nlm.nih.gov/pubmed/18539003

353.Moran, J.S., et al. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis, 1995. 20 Suppl 1: S47.

https://www.ncbi.nlm.nih.gov/pubmed/7795109

354.Yuan, Z., et al. Randomized controlled clinical trial on the efficacy of fosfomycin trometamol for uncomplicated gonococcal urethritis in men. Clin Microbiol Infect, 2016. 22: 507.

https://www.ncbi.nlm.nih.gov/pubmed/27064136

355.Lanjouw, E., et al. 2015 European guideline on the management of Chlamydia trachomatis infections. Int J STD AIDS, 2016. 27: 333.

https://www.ncbi.nlm.nih.gov/pubmed/26608577

356.Manhart, L.E., et al. Efficacy of Antimicrobial Therapy for Mycoplasma genitalium Infections. Clin Infect Dis, 2015. 61 Suppl 8: S802.

https://www.ncbi.nlm.nih.gov/pubmed/26602619

357.Khosropour, C.M., et al. Efficacy of standard therapies against Ureaplasma species and persistence among men with non-gonococcal urethritis enrolled in a randomised controlled trial. Sex Transm Infect, 2015. 91: 308.

https://www.ncbi.nlm.nih.gov/pubmed/25616607

358.Wagenlehner, F.M., et al. The Presentation, Diagnosis, and Treatment of Sexually Transmitted Infections. Dtsch Arztebl Int, 2016. 113: 11.

https://www.ncbi.nlm.nih.gov/pubmed/26931526

359.Muratani, T., et al. Single dose 1 g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae. Int J Urol, 2008. 15: 837.

https://www.ncbi.nlm.nih.gov/pubmed/18665871

360.Alexander, R.B., et al. Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome. Urology, 1998. 52: 744.

https://www.ncbi.nlm.nih.gov/pubmed/9801092

361.Alexander, R.B., et al. Chronic prostatitis: results of an Internet survey. Urology, 1996. 48: 568.

https://www.ncbi.nlm.nih.gov/pubmed/8886062

362.Zermann, D.H., et al. Neurourological insights into the etiology of genitourinary pain in men. J Urol, 1999. 161: 903.

https://www.ncbi.nlm.nih.gov/pubmed/10022711

363.Perletti, G., et al. Antimicrobial therapy for chronic bacterial prostatitis. Cochrane Database Syst Rev, 2013: CD009071.

https://www.ncbi.nlm.nih.gov/pubmed/23934982

364.Dadashpour. M, et al. Acute Prostatitis After Transrectal Ultrasound-guided Prostate Biopsy: Comparing Two Different Antibiotic Prophylaxis Regimen. Biomed Pharmacol J, 2016. 9: 593.

https://www.researchgate.net/publication/307141830

365.Schaeffer, A.J., et al. Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. J Urol, 2005. 174: 161.

https://www.ncbi.nlm.nih.gov/pubmed/15947609

366.Skerk, V., et al. Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. Int J Antimicrob Agents, 2003. 21: 457.

https://www.ncbi.nlm.nih.gov/pubmed/12727080

367.Vickovic, N., et al. Metronidazole 1.5 gram dose for 7 or 14 days in the treatment of patients with chronic prostatitis caused by Trichomonas vaginalis: A randomized study. J Chemother, 2010. 22: 364.

https://www.ncbi.nlm.nih.gov/pubmed/21123162

368.Cai, T., et al. Serenoa repens associated with Urtica dioica (ProstaMEV) and curcumin and quercitin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomised study. Int J Antimicrob Agents, 2009. 33: 549.

https://www.ncbi.nlm.nih.gov/pubmed/19181486

369.Aliaev Iu, G., et al. [Wardenafil in combined treatment of patients with chronic bacterial prostatitis]. Urologiia, 2008: 52.

https://www.ncbi.nlm.nih.gov/pubmed/19256057

370.Lipsky, B.A., et al. Treatment of bacterial prostatitis. Clin Infect Dis, 2010. 50: 1641.

https://www.ncbi.nlm.nih.gov/pubmed/20459324

371.Wise, G.J., et al. Atypical infections of the prostate. Curr Prostate Rep, 2008. 6: 86.

https://link.springer.com/article/10.1007/s11918-008-0014-2

372.Turner, J.A., et al. Validity and responsiveness of the national institutes of health chronic prostatitis symptom index. J Urol, 2003. 169: 580.

https://www.ncbi.nlm.nih.gov/pubmed/12544311

373.Zegarra Montes, L.Z., et al. Semen and urine culture in the diagnosis of chronic bacterial prostatitis. Int Braz J Urol, 2008. 34: 30.

https://www.ncbi.nlm.nih.gov/pubmed/18341719

374.Budia, A., et al. Value of semen culture in the diagnosis of chronic bacterial prostatitis: a simplified method. Scand J Urol Nephrol, 2006. 40: 326.

https://www.ncbi.nlm.nih.gov/pubmed/16916775

375.Skerk, V., et al. The role of unusual pathogens in prostatitis syndrome. Int J Antimicrob Agents, 2004. 24 Suppl 1: S53.

https://www.ncbi.nlm.nih.gov/pubmed/15364308

376.Schneider, H., et al. The 2001 Giessen Cohort Study on patients with prostatitis syndrome--an evaluation of inflammatory status and search for microorganisms 10 years after a first analysis. Andrologia, 2003. 35: 258.

https://www.ncbi.nlm.nih.gov/pubmed/14535851

377.Naber, K.G., et al., Prostatitits, epididymitis and orchitis, in: Infectious diseases, D. Armstrong & J. Cohen, Editors. 1999, Mosby: London.

378.Badalyan, R.R., et al. Chlamydial and ureaplasmal infections in patients with nonbacterial chronic prostatitis. Andrologia, 2003. 35: 263.

https://www.ncbi.nlm.nih.gov/pubmed/14535852

379.Berger, R.E., Epididymitis., in: Sexually transmitted diseases, K.K. Holmes, P.-A. Mardh, P.F. Sparling & P.J. Wiesner, Editors. 1984, McGraw-Hill: New York.

380.Robinson, A.J., et al. Acute epididymitis: why patient and consort must be investigated. Br J Urol, 1990. 66: 642.

https://www.ncbi.nlm.nih.gov/pubmed/2265337

381.Schaeffer, A.J. Prostatitis: US perspective. Int J Antimicrob Agents, 1999. 11: 205.

https://www.ncbi.nlm.nih.gov/pubmed/10394972

382.Krieger, J.N., et al. NIH consensus definition and classification of prostatitis. JAMA, 1999. 282: 236.

https://www.ncbi.nlm.nih.gov/pubmed/10422990

383.(NIDDK), Chronic prostatitis workshop. 1995: Bethesda, Maryland.

https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-03-004.html

384.Krieger, J.N., et al. Chronic pelvic pains represent the most prominent urogenital symptoms of “chronic prostatitis”. Urology, 1996. 48: 715.

https://www.ncbi.nlm.nih.gov/pubmed/8911515

385.Nickel, J.C. Effective office management of chronic prostatitis. Urol Clin North Am, 1998. 25: 677.

https://www.ncbi.nlm.nih.gov/pubmed/10026774

386.Etienne, M., et al. Performance of the urine leukocyte esterase and nitrite dipstick test for the diagnosis of acute prostatitis. Clin Infect Dis, 2008. 46: 951.

https://www.ncbi.nlm.nih.gov/pubmed/18288905

387.Meares, E.M., et al. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol, 1968. 5: 492.

https://www.ncbi.nlm.nih.gov/pubmed/4870505

388.Nickel, J.C., et al. How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J Urol, 2006. 176: 119.

https://www.ncbi.nlm.nih.gov/pubmed/16753385

389.Doble, A., et al. Ultrasonographic findings in prostatitis. Urol Clin North Am, 1989. 16: 763.

https://www.ncbi.nlm.nih.gov/pubmed/2683305

390.Papp, J.R., et al. Recommendations for the Laboratory-Based Detection of Chlamydia trachomatis and Neisseria gonorrhoeae —2014. MMWR. Recomm Rep, 2014. 63: 1.

https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6302a1.htm

391.Polascik, T.J., et al. Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol, 1999. 162: 293.

https://www.ncbi.nlm.nih.gov/pubmed/10411025

392.Wagenlehner, F.M., et al. Bacterial prostatitis. World J Urol, 2013. 31: 711.

https://www.ncbi.nlm.nih.gov/pubmed/23519458

393.Gill, B.C., et al. Bacterial prostatitis. Curr Opin Infect Dis, 2016. 29: 86.

https://www.ncbi.nlm.nih.gov/pubmed/26555038

394.Wagenlehner, F.M., et al. Prostatitis: the role of antibiotic treatment. World J Urol, 2003. 21: 105.

https://www.ncbi.nlm.nih.gov/pubmed/12687400

395.Krieger, J.N. Recurrent lower urinary tract infections in men. J New Rem Clin, 1998. 47: 4.

https://www.sciencedirect.com/science/article/abs/pii/S0022534717362924

396.Litwin, M.S., et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol, 1999. 162: 369.

https://www.ncbi.nlm.nih.gov/pubmed/10411041

397.Schaeffer, A.J., et al. Summary consensus statement: diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol 2003. 43: 1.

https://www.sciencedirect.com/science/article/abs/pii/S1569905602001914?via%3Dihub

398.Bjerklund Johansen, T.E., et al. The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur Urol, 1998. 34: 457.

https://www.ncbi.nlm.nih.gov/pubmed/9831786

399.Cai, T., et al. Clinical and microbiological efficacy of prulifloxacin for the treatment of chronic bacterial prostatitis due to Chlamydia trachomatis infection: results from a prospective, randomized and open-label study. Methods Find Exp Clin Pharmacol, 2010. 32: 39.

https://www.ncbi.nlm.nih.gov/pubmed/20383345

400.Smelov, V., et al. Chlamydia trachomatis survival in the presence of two fluoroquinolones (lomefloxacin versus levofloxacin) in patients with chronic prostatitis syndrome. Andrologia, 2005. 37: 61.

https://www.ncbi.nlm.nih.gov/pubmed/16026425

401.Ohkawa, M., et al. Antimicrobial treatment for chronic prostatitis as a means of defining the role of Ureaplasma urealyticum. Urol Int, 1993. 51: 129.

https://www.ncbi.nlm.nih.gov/pubmed/8249222

402.Jimenez-Cruz, J.F., et al. Treatment of chronic prostatitis: intraprostatic antibiotic injections under echography control. J Urol, 1988. 139: 967.

https://www.ncbi.nlm.nih.gov/pubmed/3283385

403.Mayersak, J.S. Transrectal ultrasonography directed intraprostatic injection of gentamycin-xylocaine in the management of the benign painful prostate syndrome. A report of a 5 year clinical study of 75 patients. Int Surg, 1998. 83: 347.

https://www.ncbi.nlm.nih.gov/pubmed/10096759

404.Hua, L.X., et al. [The diagnosis and treatment of acute prostatitis: report of 35 cases]. Zhonghua Nan Ke Xue, 2005. 11: 897.

https://www.ncbi.nlm.nih.gov/pubmed/16398358

405.Yoon, B.I., et al. Acute bacterial prostatitis: how to prevent and manage chronic infection? J Infect Chemother, 2012. 18: 444.

https://www.ncbi.nlm.nih.gov/pubmed/22215226

406.Ludwig, M., et al. Diagnosis and therapeutic management of 18 patients with prostatic abscess. Urology, 1999. 53: 340.

https://www.ncbi.nlm.nih.gov/pubmed/9933051

407.Chou, Y.H., et al. Prostatic abscess: transrectal color Doppler ultrasonic diagnosis and minimally invasive therapeutic management. Ultrasound Med Biol, 2004. 30: 719.

https://www.ncbi.nlm.nih.gov/pubmed/15219951

408.Çek, M., et al. Acute and Chronic Epididymitis in EAU-EBU Update Series. Eur Urol Suppl 2017. 16: 124.

https://www.sciencedirect.com/science/article/abs/pii/S1569905617300568

409.Pilatz, A., et al. Acute epididymitis revisited: impact of molecular diagnostics on etiology and contemporary guideline recommendations. Eur Urol, 2015. 68: 428.

https://www.ncbi.nlm.nih.gov/pubmed/25542628

410.Harnisch, J.P., et al. Aetiology of acute epididymitis. Lancet, 1977. 1: 819.

https://www.ncbi.nlm.nih.gov/pubmed/67333

411.Shigemura, K., et al. Risk factors for febrile genito-urinary infection in the catheterized patients by with spinal cord injury-associated chronic neurogenic lower urinary tract dysfunction evaluated by urodynamic study and cystography: a retrospective study. World J Urol, 2020. 38: 733.

https://www.ncbi.nlm.nih.gov/pubmed/30949801

412.Street, E., et al. The 2016 European guideline on the management of epididymo-orchitis. IUSTI, 2016.

http://www.iusti.org/regions/europe/pdf/2013/Epididymo-orchitis-2013IUSTI_WHO.pdf

413.Chirwa, M., et al. United Kingdom British association for sexual health and HIV national guideline for the management of epididymo-orchitis, 2020. Int J STD AIDS, 2021. 32: 884.

https://www.ncbi.nlm.nih.gov/pubmed/34009058

414.Abbara, A., et al. Etiology and management of genitourinary tuberculosis. Nat Rev Urol, 2011. 8: 678.

https://www.ncbi.nlm.nih.gov/pubmed/22157940

415.Zitek, T., et al. Assessing the Utility of Ultrasound and Urinalysis for Patients with Possible Epididymo-Orchitis - A Retrospective Study. Open Access Emerg Med, 2020. 12: 47.

https://www.ncbi.nlm.nih.gov/pubmed/32214857

416.Capet, J., et al. Is follow-up ultrasound necessary after acute epididymitis? A retrospective analysis from a large university hospital. Scand J Urol, 2018. 52: 445.

https://www.ncbi.nlm.nih.gov/pubmed/30600755

417.Sadahira, T., et al. Clinical pharmacokinetics of oral levofloxacin and sitafloxacin in epididymal tissue. J Infect Chemother, 2017. 23: 214.

https://www.ncbi.nlm.nih.gov/pubmed/28089362

418.Street, E., et al. BASHH 2010 United Kingdom national guideline for the management of epididymo-orchitis. 2010.

https://www.ncbi.nlm.nih.gov/pubmed/21729951

419.Fifer, H., et al. 2018 UK national guideline for the management of infection with Neisseria gonorrhoeae. Int J STD AIDS, 2020. 31: 4.

https://www.ncbi.nlm.nih.gov/pubmed/31870237

420.Eickhoff, J.H., et al. A double-blind, randomized, controlled multicentre study to compare the efficacy of ciprofloxacin with pivampicillin as oral therapy for epididymitis in men over 40 years of age. BJU Int, 1999. 84: 827.

https://www.ncbi.nlm.nih.gov/pubmed/10532980

421.Banyra, O., et al. Acute epididymo-orchitis: relevance of local classification and partner’s follow-up. Cent Eur J Urol, 2019. 72: 324.

https://www.ncbi.nlm.nih.gov/pubmed/31720038

422.Pilatz, A., et al. Impact of Bacterial Epididymitis on Semen Quality after Antibiotic Treatment. J Urol, 2012. 187: e443.

https://www.auajournals.org/doi/pdf/10.1016/j.juro.2012.02.1199

423.Haddadeen, C., et al. Comparative regional audit of urology and genito-urinary departments in the management of acute epididymo-orchitis. HIV Medicine, 2010. 11: 45.

https://www.researchgate.net/publication/295130036

424.Nicholson, A., et al. Management of epididymo-orchitis in primary care: results from a large UK primary care database. Br J Gen Pract, 2010. 60: e407.

https://www.ncbi.nlm.nih.gov/pubmed/20883615

425.Andersen, B., et al. Impact of intensified testing for urogenital Chlamydia trachomatis infections: a randomised study with 9-year follow-up. Sex Transm Infect, 2011. 87: 156.

https://www.ncbi.nlm.nih.gov/pubmed/21097811

426.Chennamsetty, A., et al. Contemporary diagnosis and management of Fournier’s gangrene. Ther Adv Urol, 2015. 7: 203.

https://www.ncbi.nlm.nih.gov/pubmed/26445600

427.Eke, N. Fournier’s gangrene: a review of 1726 cases. Br J Surg, 2000. 87: 718.

https://www.ncbi.nlm.nih.gov/pubmed/10848848

428.Subrahmanyam, U., et al. Honey dressing beneficial in treatment of fournier’s gangrene. Indian J Surg, 2004. 66: 75.

https://www.researchgate.net/publication/289257622

429.Jallali, N., et al. Hyperbaric oxygen as adjuvant therapy in the management of necrotizing fasciitis. Am J Surg, 2005. 189: 462.

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed10&NEWS=N&AN=40488245

430.Karian, L.S., et al. Reconstruction of Defects After Fournier Gangrene: A Systematic Review. Eplasty, 2015. 15: e18.

https://www.ncbi.nlm.nih.gov/pubmed/26171090

431.Furr, J., et al. Contemporary Trends in the Inpatient Management of Fournier’s Gangrene: Predictors of Length of Stay and Mortality Based on Population-based Sample. Urology, 2017. 102: 79.

https://www.ncbi.nlm.nih.gov/pubmed/27693572

432.Kim, S.Y., et al. A contemporary analysis of Fournier gangrene using the National Surgical Quality Improvement Program. Urology, 2015. 85: 1052.

https://www.ncbi.nlm.nih.gov/pubmed/25770725

433.Sorensen, M.D., et al. Fournier’s Gangrene: Epidemiology and Outcomes in the General US Population. Urol Int, 2016. 97: 249.

https://www.ncbi.nlm.nih.gov/pubmed/27172977

434.Roghmann, F., et al. Is there a need for the Fournier’s gangrene severity index? Comparison of scoring systems for outcome prediction in patients with Fournier’s gangrene. BJU Int, 2012. 110: 1359.

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed14&NEWS=N&AN=51959313

435.Lauerman, M.H., et al. Less is more? Antibiotic duration and outcomes in Fournier’s gangrene. J Trauma Acute Care Surg, 2017. 83: 443.

https://www.ncbi.nlm.nih.gov/pubmed/28538648

436.Li, C., et al. Hyperbaric oxygen therapy as an adjuvant therapy for comprehensive treatment of Fournier’s gangrene. Urol Int, 2015. 94: 453.

https://www.ncbi.nlm.nih.gov/pubmed/25677386

437.Stevens, D.L., et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis, 2014. 59: 147.

https://www.ncbi.nlm.nih.gov/pubmed/24947530

438.Lyu, Z., et al. Human papillomavirus in semen and the risk for male infertility: a systematic review and meta-analysis. BMC Infect Dis, 2017. 17: 714.

https://www.ncbi.nlm.nih.gov/pubmed/29121862

439.Rodriguez-Alvarez, M.I., et al. Prevalence and Risk Factors of Human Papillomavirus in Male Patients: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health, 2018. 15: 2210.

https://www.ncbi.nlm.nih.gov/pubmed/30309014

440.Vaccarella, S., et al. Clustering of human papillomavirus (HPV) types in the male genital tract: the HPV in men (HIM) study. J Infect Dis, 2011. 204: 1500.

https://www.ncbi.nlm.nih.gov/pubmed/21908729

441.Nakashima, K., et al. Risk factors for human papillomavirus detection in urine samples of heterosexual men visiting urological clinics in Japan. J Infect Chemother, 2018. 24: 713.

https://www.ncbi.nlm.nih.gov/pubmed/29759898

442.Luttmer, R., et al. Presence of human papillomavirus in semen in relation to semen quality. Hum Reprod, 2016. 31: 280.

https://www.ncbi.nlm.nih.gov/pubmed/26724799

443.Souho, T., et al. Human papillomavirus infection and fertility alteration: a systematic review. PLoS One, 2015. 10: e0126936.

https://www.ncbi.nlm.nih.gov/pubmed/25992782

444.Azevedo, J., et al. Epidemiology of human papillomavirus on anogenital warts in Portugal - The HERCOLES study. J Eur Acad Dermatol Venereol, 2017. 31: 1342.

https://www.ncbi.nlm.nih.gov/pubmed/28485812

445.Wei, F., et al. Sex Differences in the Incidence and Clearance of Anogenital Human Papillomavirus Infection in Liuzhou, China: An Observational Cohort Study. Clin Infect Dis, 2020. 70: 82.

https://www.ncbi.nlm.nih.gov/pubmed/30852604

446.Harder, T., et al. Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review. BMC Med, 2018. 16: 110.

https://www.ncbi.nlm.nih.gov/pubmed/30016957

447.Shigeishi, H., et al. Risk Factors for Oral Human Papillomavirus Infection in Healthy Individuals: A Systematic Review and Meta-Analysis. J Clin Med Res, 2016. 8: 721.

https://www.ncbi.nlm.nih.gov/pubmed/27635177

448.Tam, S., et al. The epidemiology of oral human papillomavirus infection in healthy populations: A systematic review and meta-analysis. Oral Oncol, 2018. 82: 91.

https://www.ncbi.nlm.nih.gov/pubmed/29909908

449.Dalla Torre, D., et al. The impact of sexual behavior on oral HPV infections in young unvaccinated adults. Clin Oral Investig, 2016. 20: 1551.

https://www.ncbi.nlm.nih.gov/pubmed/26526324

450.Geskus R.B., et al. Incidence and clearance of anal high-risk human papillomavirus in HIV-positive men who have sex with men: estimates and risk factors. AIDS (london, england), 2016. 30: 37.

https://www.ncbi.nlm.nih.gov/pubmed/26355673

451.Hebnes, J.B., et al. Prevalence of genital human papillomavirus among men in Europe: systematic review and meta-analysis. J Sex Med, 2014. 11: 2630.

https://www.ncbi.nlm.nih.gov/pubmed/25088239

452.Kaderli, R., et al. The impact of smoking on HPV infection and the development of anogenital warts. Int J Colorectal Dis, 2014. 29: 899.

https://www.ncbi.nlm.nih.gov/pubmed/24935346

453.Liu, M., et al. Transmission of genital human papillomavirus infection in couples: a population-based cohort study in rural China. Sci Rep, 2015. 5: 10986.

https://www.ncbi.nlm.nih.gov/pubmed/26204471

454.Taylor, S., et al. The incidence, clearance and persistence of non-cervical human papillomavirus infections: a systematic review of the literature. BMC Infect Dis, 2016. 16: 293.

https://www.ncbi.nlm.nih.gov/pubmed/27301867

455.Albero, G., et al. Male circumcision and prevalence of genital human papillomavirus infection in men: a multinational study. BMC Infect Dis, 2013. 13: 18.

https://www.ncbi.nlm.nih.gov/pubmed/23327450

456.Lam, J.U., et al. Condom use in prevention of Human Papillomavirus infections and cervical neoplasia: systematic review of longitudinal studies. J Med Screen, 2014. 21: 38.

https://www.ncbi.nlm.nih.gov/pubmed/24488594

457.Larke, N., et al. Male circumcision and human papillomavirus infection in men: a systematic review and meta-analysis. J Infect Dis, 2011. 204: 1375.

https://www.ncbi.nlm.nih.gov/pubmed/21965090

458.Liu, Z., et al. Penises not required: a systematic review of the potential for human papillomavirus horizontal transmission that is non-sexual or does not include penile penetration. Sex Health, 2016. 13: 10.

https://www.ncbi.nlm.nih.gov/pubmed/26433493

459.Albero, G., et al. Male circumcision and genital human papillomavirus: a systematic review and meta-analysis. Sex Transm Dis, 2012. 39: 104.

https://www.ncbi.nlm.nih.gov/pubmed/22249298

460.Zaak, D., et al. Recurrence of condylomata acuminata of the urethra after conventional and fluorescence-controlled Nd:YAG laser treatment. Urology, 2003. 61: 1011.

https://www.ncbi.nlm.nih.gov/pubmed/12736026

461.Vives, A., et al. Urethral condylomas in men: experience in 123 patients without previous treatment. Int J STD AIDS, 2016. 27: 39.

https://www.ncbi.nlm.nih.gov/pubmed/25712107

462.Gilson, R., et al. 2019 IUSTI-Europe guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol, 2020. 34: 1644.

https://www.ncbi.nlm.nih.gov/pubmed/32735077

463.Edwards, L., et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol, 1998. 134: 25.

https://www.ncbi.nlm.nih.gov/pubmed/9449906

464.Saiag, P., et al. Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study. Br J Dermatol, 2009. 161: 904.

https://www.ncbi.nlm.nih.gov/pubmed/19466962

465.Grillo-Ardila, C.F., et al. Imiquimod for anogenital warts in non-immunocompromised adults. Cochrane Database Syst Rev, 2014: CD010389.

https://www.ncbi.nlm.nih.gov/pubmed/25362229

466.Tatti, S., et al. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol, 2008. 111: 1371.

https://www.ncbi.nlm.nih.gov/pubmed/18515521

467.Puviani, M., et al. Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO(2) ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial. Int J STD AIDS, 2019. 30: 131.

https://www.ncbi.nlm.nih.gov/pubmed/30236042

468.Werner, R.N., et al. Self-administered interventions for anogenital warts in immunocompetent patients: a systematic review and meta-analysis. Sex Transm Infect, 2017. 93: 155.

https://www.ncbi.nlm.nih.gov/pubmed/27803240

469.Camargo, C.L., et al. A prospective, open, comparative study of 5% potassium hydroxide solution versus cryotherapy in the treatment of genital warts in men. An Bras Dermatol, 2014. 89: 236.

https://www.ncbi.nlm.nih.gov/pubmed/24770498

470.Kodner, C.M., et al. Management of genital warts. Am Fam Physician, 2004. 70: 2335.

https://www.ncbi.nlm.nih.gov/pubmed/15617297

471.Scheinfeld, N., et al. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J, 2006. 12: 5.

https://www.ncbi.nlm.nih.gov/pubmed/16638419

472.Barton, S., et al. Effectiveness of topical and ablative therapies in treatment of anogenital warts: a systematic review and network meta-analysis. BMJ Open, 2019. 9: e027765.

https://www.ncbi.nlm.nih.gov/pubmed/31676644

473.Tobian, A.A., et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med, 2009. 360: 1298.

https://www.ncbi.nlm.nih.gov/pubmed/19321868

474.Schmeler, K.M., et al. Expanding the benefits of HPV vaccination to boys and men. Lancet, 2016. 387: 1798.

https://www.ncbi.nlm.nih.gov/pubmed/27203488

475.Rosales, R., et al. Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine. Hum Gene Ther, 2014. 25: 1035.

https://www.ncbi.nlm.nih.gov/pubmed/25275724

476.Mikamo, H., et al. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study. Vaccine, 2019. 37: 1651.

https://www.ncbi.nlm.nih.gov/pubmed/30797638

477.Bergman, H., et al. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Cochrane Database Syst Rev, 2019. 2019: CD013479.

https://www.ncbi.nlm.nih.gov/pubmed/31755549

478.Dibble, K.E., et al. A Systematic Literature Review of HPV Vaccination Barriers Among Adolescent and Young Adult Males. J Adolesc Young Adult Oncol, 2019. 8: 495.

https://www.ncbi.nlm.nih.gov/pubmed/31090474

479.Richman A.R., et al. A randomized intervention study to evaluate whether electronic messaging can increase HPV vaccine uptake and knowledge. J Lower Genital Tract Dis, 2016. 20: S28.

https://journals.lww.com/jlgtd/Fulltext/2016/04001/2016_ASCCP_Poster_Presentation_Abstracts.2.aspx

480.Dabestani, N., et al. Time Trends in First-Episode Genital Herpes Simplex Virus Infections in an Urban Sexually Transmitted Disease Clinic. Sex Transm Dis, 2019. 46: 795.

https://www.ncbi.nlm.nih.gov/pubmed/31764767

481.Yousuf, W., et al. Herpes simplex virus type 1 in Europe: systematic review, meta-analyses and meta-regressions. BMJ Glob Health, 2020. 5.

https://www.ncbi.nlm.nih.gov/pubmed/32675066

482.AlMukdad, S., et al. Epidemiology of herpes simplex virus type 1 and genital herpes in Australia and New Zealand: systematic review, meta-analyses and meta-regressions. Epidemiol Infect, 2023. 151: e33.

https://www.ncbi.nlm.nih.gov/pubmed/36750224

483.Alareeki, A., et al. Epidemiology of herpes simplex virus type 2 in Europe: systematic review, meta-analyses, and meta-regressions. Lancet Reg Health Eur, 2023. 25: 100558.

https://www.ncbi.nlm.nih.gov/pubmed/36818238

484.AlMukdad, S., et al. Epidemiology of herpes simplex virus type 2 in Asia: A systematic review, meta-analysis, and meta-regression. Lancet Reg Health West Pac, 2021. 12: 100176.

https://www.ncbi.nlm.nih.gov/pubmed/34527970

485.AlMukdad, S., et al. Epidemiology of Herpes Simplex Virus Type 2 in Canada, Australia, and New Zealand: Systematic Review, Meta-Analyses, and Meta-Regressions. Sex Transm Dis, 2022. 49: 403.

https://www.ncbi.nlm.nih.gov/pubmed/35608096

486.Magaret, A.S., et al. Effect of Condom Use on Per-act HSV-2 Transmission Risk in HIV-1, HSV-2-discordant Couples. Clin Infect Dis, 2016. 62: 456.

https://www.ncbi.nlm.nih.gov/pubmed/26578538

487.Hochberg, C.H., et al. Population and dyadic-based seroincidence of herpes simplex virus-2 and syphilis in southern India. Sex Transm Infect, 2015. 91: 375.

https://www.ncbi.nlm.nih.gov/pubmed/25605970

488.Sasso, B.M., et al. Herpes simplex virus mucocutaneous tumoural lesions - Systematic review. J Clin Virol, 2020. 123: 104246.

https://www.ncbi.nlm.nih.gov/pubmed/31927151

489.Johnston, C., et al. Highly conserved intragenic HSV-2 sequences: Results from next-generation sequencing of HSV-2 U(L) and U(S) regions from genital swabs collected from 3 continents. Virology, 2017. 510: 90.

https://www.ncbi.nlm.nih.gov/pubmed/28711653

490.Liu, J., et al. Development and evaluation of the quantitative real-time PCR assay in detection and typing of herpes simplex virus in swab specimens from patients with genital herpes. Int J Clin Exp Med, 2015. 8: 18758.

https://www.ncbi.nlm.nih.gov/pubmed/26770492

491.Young, S., et al. Multicenter evaluation of the Luminex® ARIES® HSV 1&2 Assay for the detection of herpes simplex virus types 1 and 2 in cutaneous and mucocutaneous lesion specimens. Expert Rev Mol Diagn, 2016. 16: 1241.

https://www.ncbi.nlm.nih.gov/pubmed/27771977

492.Schremser, V., et al. Polymerase chain reaction for the diagnosis of herpesvirus infections in dermatology : Analysis of clinical data. Wien Klin Wochenschr, 2020. 132: 35.

https://www.ncbi.nlm.nih.gov/pubmed/31820101

493.Binnicker, M.J., et al. Automated processing, extraction and detection of herpes simplex virus types 1 and 2: A comparative evaluation of three commercial platforms using clinical specimens. J Clin Virol, 2017. 89: 30.

https://www.ncbi.nlm.nih.gov/pubmed/28226272

494.Patwardhan, V., et al. A Comparative Analysis of Polymerase Chain Reaction and Direct Fluorescent Antibody Test for Diagnosis of Genital Herpes. J Lab Physicians, 2017. 9: 53.

https://www.ncbi.nlm.nih.gov/pubmed/28042218

495.Patel, E.U., et al. Precision of the Kalon Herpes Simplex Virus Type 2 IgG ELISA: an international inter-laboratory assessment. BMC Infect Dis, 2015. 15: 398.

https://www.ncbi.nlm.nih.gov/pubmed/26423888

496.Patwardhan, V., et al. Role of type-specific herpes simplex virus-1 and 2 serology as a diagnostic modality in patients with clinically suspected genital herpes: A comparative study in Indian population from a tertiary care hospital. Indian J Pathol Microbiol, 2016. 59: 318.

https://www.ncbi.nlm.nih.gov/pubmed/ 27510668

497.Liu, T., et al. Production of a fragment of glycoprotein G of herpes simplex virus type 2 and evaluation of its diagnostic potential. Singapore Med J, 2015. 56: 346.

https://www.ncbi.nlm.nih.gov/pubmed/25532518

498.Al-Shobaili, H., et al. Evaluation of the HerpeSelect Express rapid test in the detection of herpes simplex virus type 2 antibodies in patients with genital ulcer disease. J Clin Lab Anal, 2015. 29: 43.

https://www.ncbi.nlm.nih.gov/pubmed/24687953

499.Shevlin, E., et al. Comparative performance of the Uni-Gold™ HSV-2 Rapid: a point-of-care HSV-2 diagnostic test in unselected sera from a reference laboratory. J Clin Virol, 2014. 61: 378.

https://www.ncbi.nlm.nih.gov/pubmed/25200648

500.Wald, A., et al. Helicase–Primase Inhibitor Pritelivir for HSV-2 Infection. New Engl J Med, 370: 201.

https://www.nejm.org/doi/10.1056/NEJMoa1301150

501.Takada, A., et al. Statistical analysis of Amenamevir (ASP2151) between pharmacokinetics and clinical efficacies with non-linear effect model for the treatment of genital herpes. Clin Pharmacol Drug Dev, 2014. 3: 365.

https://www.ncbi.nlm.nih.gov/pubmed/27129009

502.Kawashima, M., et al. Single-Dose, Patient-Initiated Amenamevir Therapy for Recurrent Genital Herpes: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study. Open Forum Infect Dis, 2022. 9: ofac494.

https://www.ncbi.nlm.nih.gov/pubmed/36267254

503.You, Y., et al. Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients. J Dermatol, 2015. 42: 596.

https://www.ncbi.nlm.nih.gov/pubmed/25819042

504.Yi, T.J., et al. Valacyclovir therapy does not reverse herpes-associated alterations in cervical immunology: a randomized, placebo-controlled crossover trial. J Infect Dis, 2014. 210: 708.

https://www.ncbi.nlm.nih.gov/pubmed/24664172

505.Wald, A., et al. Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial. Jama, 2016. 316: 2495.

https://www.ncbi.nlm.nih.gov/pubmed/27997653

506.Mark, K.E., et al. Three phase III randomized controlled trials of topical resiquimod 0.01-percent gel to reduce anogenital herpes recurrences. Antimicrob Agents Chemother, 2014. 58: 5016.

https://www.ncbi.nlm.nih.gov/pubmed/24709264

507.Khemis, A., et al. Evaluation of the activity and safety of CS21 barrier genital gel® compared to topical aciclovir and placebo in symptoms of genital herpes recurrences: a randomized clinical trial. J Eur Acad Dermatol Venereol, 2014. 28: 1158.

https://www.ncbi.nlm.nih.gov/pubmed/24010876

508.Van Wagoner, N., et al. Effects of Different Doses of GEN-003, a Therapeutic Vaccine for Genital Herpes Simplex Virus-2, on Viral Shedding and Lesions: Results of a Randomized Placebo-Controlled Trial. J Infect Dis, 2018. 218: 1890.

https://www.ncbi.nlm.nih.gov/pubmed/29982727

509.Flechtner, J.B., et al. Immune responses elicited by the GEN-003 candidate HSV-2 therapeutic vaccine in a randomized controlled dose-ranging phase 1/2a trial. Vaccine, 2016. 34: 5314.

https://www.ncbi.nlm.nih.gov/pubmed/27642130

510.Bernstein, D.I., et al. Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized Trial. J Infect Dis, 2017. 215: 856.

https://www.ncbi.nlm.nih.gov/pubmed/28329211

511.Bernstein, D.I., et al. Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease. Vaccine, 2019. 37: 3443.

https://www.ncbi.nlm.nih.gov/pubmed/31103365

512.Dropulic, L.K., et al. A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection. J Infect Dis, 2019. 220: 990.

https://www.ncbi.nlm.nih.gov/pubmed/31058977

513.Chandra, J., et al. Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial. PLoS One, 2019. 14: e0226320.

https://www.ncbi.nlm.nih.gov/pubmed/31846475

514.Grabowski, M.K., et al. Herpes Simplex [corrected] Virus Type 2 Shedding From Male Circumcision Wounds in Rakai, Uganda. J Infect Dis, 2015. 212: 1613.

https://www.ncbi.nlm.nih.gov/pubmed/25943201

515.Osiecka, B.J., et al. Photodynamic Therapy with Red Light and 5-Aminolaevulinic Acid for Herpes Simplex Recurrence: Preliminary Results. Acta Derm Venereol, 2017. 97: 1239.

https://www.ncbi.nlm.nih.gov/pubmed/28681068

516.Vallely, A.J., et al. Dorsal longitudinal foreskin cut is associated with reduced risk of HIV, syphilis and genital herpes in men: a cross-sectional study in Papua New Guinea. J Int AIDS Soc, 2017. 20: 21358.

https://www.ncbi.nlm.nih.gov/pubmed/28406272

517.Abdool Karim, S.S., et al. Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. N Engl J Med, 2015. 373: 530.

https://www.ncbi.nlm.nih.gov/pubmed/26244306

518.European Center for Disease Pervention and Control/World Health Organisation. Tuberculosis surveillance and monitoring in Europe 2021 (2019 data). ECDC/WHO. ISBN 978-92-9498-534-7.

https://www.ecdc.europa.eu/sites/default/files/documents/tuberculosis-surveillance-monitoring-Europe-2021.pdf

519.Hayward, S.E., et al. Extrapulmonary tuberculosis among migrants in Europe, 1995 to 2017. Clin Microbiol Infect, 2021. 27: 1347 e1.

https://www.ncbi.nlm.nih.gov/pubmed/33352301

520.Lawn, S.D., et al. Tuberculosis. Lancet, 2011. 378: 57.

https://www.ncbi.nlm.nih.gov/pubmed/21420161

521.Kang, W., et al. Epidemiology of concurrent extrapulmonary tuberculosis in inpatients with extrapulmonary tuberculosis lesions in China: a large-scale observational multi-centre investigation. Int J Infect Dis, 2022. 115: 79.

https://www.ncbi.nlm.nih.gov/pubmed/34781005

522.Vynnycky, E., et al. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect, 1997. 119: 183.

https://www.ncbi.nlm.nih.gov/pubmed/9363017

523.WHO. WHO consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment. ISBN 978-92-4-000150-3, 2020.

https://www.who.int/publications/i/item/9789240001503

524.Lewinsohn, D.M., et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis, 2017. 64: 111.

https://www.ncbi.nlm.nih.gov/pubmed/28052967

525.European Centre for Disease Prevention and Control. Mastering the basics of TB control: Development of a handbook on TB diagnostic methods. Stockholm, ECDC, 2011. ISBN 978-92-9193-242-9.

https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/1105_TER_Basics_TB_control.pdf

526.Ye, Y., et al. Clinical Features and Drug-Resistance Profile of Urinary Tuberculosis in South-Western China: A Cross-sectional Study. Medicine (Baltimore), 2016. 95: e3537.

https://www.ncbi.nlm.nih.gov/pubmed/27175652

527.Pingle, P., et al. Evaluation of Microscopy, Culture and PCR Methods in the Laboratory Diagnosis of Genito-urinary Tuberculosis. Am J Infect Dis Microbiol, 2014. 2: 17.

http://pubs.sciepub.com/ajidm/2/1/4

528.Sun, L., et al. Rapid diagnosis in early stage renal tuberculosis by real-time polymerase chain reaction on renal biopsy specimens. Int J Tuberc Lung Dis, 2010. 14: 341.

https://www.ncbi.nlm.nih.gov/pubmed/20132626

529.Kumar, P., et al. Diagnosis of renal tuberculosis by real-time polymerase chain reaction in renal biopsy sample. World J Pharma Med Res, 2017. 3: 285.

https://www.wjpmr.com/home/article_abstract/709

530.World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection 2021 update. ISBN 978-92-4-002941-5

531.WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection. Web Annex 4. Evidence synthesis and analysis. ISBN 978-92-4-001026-0.

https://iris.who.int/handle/10665/334150

532.Hemal, A.K., et al. Polymerase chain reaction in clinically suspected genitourinary tuberculosis: comparison with intravenous urography, bladder biopsy, and urine acid fast bacilli culture. Urology, 2000. 56: 570.

https://www.ncbi.nlm.nih.gov/pubmed/11018606

533.Muttarak, M., et al. Tuberculous epididymitis and epididymo-orchitis: sonographic appearances. AJR Am J Roentgenol, 2001. 176: 1459.

https://www.ncbi.nlm.nih.gov/pubmed/11373214

534.Yang, D.M., et al. Differential diagnosis of focal epididymal lesions with gray scale sonographic, color Doppler sonographic, and clinical features. J Ultrasound Med, 2003. 22: 135.

https://www.ncbi.nlm.nih.gov/pubmed/12562118

535.Li, S., et al. A better understanding of testicular and/or epididymal tuberculosis based on clinical, ultrasonic, computed tomography, and magnetic resonance imaging features at a high-volume institute in the modern era. Quant Imaging Med Surg, 2021. 11: 2465.

https://www.ncbi.nlm.nih.gov/pubmed/34079716

536.Jing, J., et al. Vas deferens sonographic appearances of tuberculosis lesions of 19 cases of male genital systemic tuberculosis. Medicine (Baltimore), 2019. 98: e14843.

https://www.ncbi.nlm.nih.gov/pubmed/30882677

537.Yang, D.M., et al. Chronic tuberculous epididymitis: color Doppler US findings with histopathologic correlation. Abdom Imaging, 2000. 25: 559.

https://www.ncbi.nlm.nih.gov/pubmed/10931999

538.Rui, X., et al. Ultrasonographic diagnosis and typing of renal tuberculosis. Int J Urol, 2008. 15: 135.

https://www.ncbi.nlm.nih.gov/pubmed/18269447

539.Radwan, A., et al. Multimodality Imaging of Genitourinary Tuberculosis. Curr Probl Diagn Radiol, 2021. 50: 867.

https://www.ncbi.nlm.nih.gov/pubmed/33272721

540.Baumgarten, D.A., et al. Imaging and radiologic management of upper urinary tract infections. Urol Clin North Am, 1997. 24: 545.

https://www.ncbi.nlm.nih.gov/pubmed/9275978

541.Muttarak, M., et al. Tuberculosis of the genitourinary tract: imaging features with pathological correlation. Singapore Med J, 2005. 46: 568.

https://www.ncbi.nlm.nih.gov/pubmed/16172781

542.Wang, Y., et al. Computerised tomography and intravenous pyelography in urinary tuberculosis: a retrospective descriptive study. Int J Tuberc Lung Dis, 2015. 19: 1441.

https://www.ncbi.nlm.nih.gov/pubmed/26614184

543.Sataa, S., et al. Imaging findings of urinary tuberculosis on computerized tomography versus excretory urography: Through 46 confirmed cases. Tunisie Medicale, 2014. 92: 743.

https://www.ncbi.nlm.nih.gov/pubmed/25879600

544.Wang, L.J., et al. Imaging findings of urinary tuberculosis on excretory urography and computerized tomography. J Urol, 2003. 169: 524.

https://www.ncbi.nlm.nih.gov/pubmed/12544301

545.Birnbaum, B.A., et al. Extrarenal genitourinary tuberculosis: CT appearance of calcified pipe-stem ureter and seminal vesicle abscess. J Comput Assist Tomogr, 1990. 14: 653.

https://www.ncbi.nlm.nih.gov/pubmed/2370364

546.Jung, Y.Y., et al. Genitourinary tuberculosis: comprehensive cross-sectional imaging. AJR Am J Roentgenol, 2005. 184: 143.

https://www.ncbi.nlm.nih.gov/pubmed/15615965

547.Wang, L.J., et al. CT features of genitourinary tuberculosis. J Comput Assist Tomogr, 1997. 21: 254.

https://www.ncbi.nlm.nih.gov/pubmed/9071295

548.Sharma, J.B., et al. Female genital tuberculosis: Revisited. Indian J Med Res, 2018. 148: S71.

https://www.ncbi.nlm.nih.gov/pubmed/30964083

549.Mantica, G., et al. Genitourinary Tuberculosis: A Comprehensive Review of a Neglected Manifestation in Low-Endemic Countries. Antibiotics (Basel), 2021. 10.

https://www.ncbi.nlm.nih.gov/pubmed/34827337

550.da Rocha, E.L., et al. Abdominal tuberculosis: a radiological review with emphasis on computed tomography and magnetic resonance imaging findings. Radiol Bras, 2015. 48: 181.

https://www.ncbi.nlm.nih.gov/pubmed/26185345

551.Cheng, Y., et al. Multiparametric Magnetic Resonance Imaging Characteristics of Prostate Tuberculosis. Korean J Radiol, 2015. 16: 846.

https://www.ncbi.nlm.nih.gov/pubmed/26175584

552.Ahmadi, F., et al. Hysterosalpingographic Appearances of Female Genital Tract Tuberculosis: Part II: Uterus. Int J Fertil Steril, 2014. 8: 13.

https://www.ncbi.nlm.nih.gov/pubmed/24696765

553.Ahmadi, F., et al. Hysterosalpingographic appearances of female genital tract tuberculosis: part I. Fallopian tube. Int J Fertil Steril, 2014. 7: 245.

https://www.ncbi.nlm.nih.gov/pubmed/24520493

554.Netter, A., et al. [Tuberculous endo-uterine symphysis; an anatomo-clinical and radiologically characteristic syndrome]. Gynecol Obstet (Paris), 1955. 54: 19.

https://www.ncbi.nlm.nih.gov/pubmed/14391756

555.World Health Organization. WHO consolidated guidelines on tuberculosis Module 4: Treatment: Drug-susceptible tuberculosis treatment 2022. ISBN 978-92-4-004812-6.

https://www.who.int/publications/i/item/9789240007048

556.European Centre for Disease Pervention and Control. European Union Standards for Tuberculosis Care 2017 update. ISBN 978-92-9498-247-6.

https://www.ecdc.europa.eu/sites/default/files/documents/ESTC-leaflet-September-2018.pdf

557.Huang, Y., et al. Surgical management of tuberculous epididymo-orchitis: a retrospective study of 81 cases with long-term follow-up. BMC Infect Dis, 2021. 21: 1068.

https://www.ncbi.nlm.nih.gov/pubmed/34654377

558.Mittal, A., et al. Surgical Management of Genitourinary Tuberculosis: our Experience and review of literature. Pol Przegl Chir, 2020. 92: 1.

https://www.ncbi.nlm.nih.gov/pubmed/33408264

559.Figueiredo, A.A., et al. Epidemiology of urogenital tuberculosis worldwide. Int J Urol, 2008. 15: 827.

https://www.ncbi.nlm.nih.gov/pubmed/18637157

560.Mochalova, T.P., et al. Reconstructive surgery for treatment of urogenital tuberculosis: 30 years of observation. World J Surg, 1997. 21: 511.

https://www.ncbi.nlm.nih.gov/pubmed/9204739

561.Gupta, N.P., et al. Reconstructive surgery for the management of genitourinary tuberculosis: a single center experience. J Urol, 2006. 175: 2150.

https://www.ncbi.nlm.nih.gov/pubmed/16697825

562.Kumar, A., et al. Can kidneys be saved in patients with urinary tuberculosis? A study in the era of modern chemotherapy and surgical armamentarium. Int J Urol, 2019. 26: 551.

https://www.ncbi.nlm.nih.gov/pubmed/30803052

563.Pal, D.K., et al. Role of surgical intervention in genitourinary tuberculosis in the era of modern anti-tubercular chemotherapy. Sch. J. App. Med. Sci, 2015. 3: 1608.

https://www.researchgate.net/publication/279925411

564.Li, X., et al. A Clinical Comparative Analysis of Retroperitoneal Laparoscopic Tuberculous Nephrectomy and Open Tuberculous Nephrectomy. J Laparoendosc Adv Surg Tech A, 2019. 29: 909.

https://www.ncbi.nlm.nih.gov/pubmed/30932738

565.Zhang, S., et al. Open surgery versus retroperitoneal laparoscopic nephrectomy for renal tuberculosis: a retrospective study of 120 patients. PeerJ, 2016. 4: e2708.

https://www.ncbi.nlm.nih.gov/pubmed/27917313

566.Kim, H.H., et al. Laparoscopic nephrectomy for nonfunctioning tuberculous kidney. J Endourol, 2000. 14: 433.

https://www.ncbi.nlm.nih.gov/pubmed/10958566

567.Han, W.K., et al. The feasibility of laparoendoscopic single-site nephrectomy: initial experience using home-made single-port device. Urology, 2010. 76: 862.

https://www.ncbi.nlm.nih.gov/pubmed/20110116

568.Hemal, A.K., et al. Comparison of retroperitoneoscopic nephrectomy with open surgery for tuberculous nonfunctioning kidneys. J Urol, 2000. 164: 32.

https://www.ncbi.nlm.nih.gov/pubmed/10840418

569.ECDC. Annual Epidemiological Report 2016 – Healthcare-associated infections acquired in intensive care units. 2016.

https://www.ecdc.europa.eu/en/publications-data/healthcare-associated-infections-acquired-intensive-care-units-annual

570.NHSN. Procedure-associated Module 9: Surgical Site Infection (SSI) Event. 2017.

https://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf

571.Tanner, J., et al. Surgical hand antisepsis to reduce surgical site infection. Cochrane Database Syst Rev, 2016. 2016: CD004288.

https://www.ncbi.nlm.nih.gov/pubmed/26799160

572.Webster, J., et al. Preoperative bathing or showering with skin antiseptics to prevent surgical site infection. Cochrane Database Syst Rev, 2015. 2015: CD004985.

https://www.ncbi.nlm.nih.gov/pubmed/25927093

573.Tanner, J., et al. Preoperative hair removal to reduce surgical site infection. Cochrane Database Syst Rev, 2011: CD004122.

https://www.ncbi.nlm.nih.gov/pubmed/22071812

574.Arnold, A., et al. Preoperative Mechanical Bowel Preparation for Abdominal, Laparoscopic, and Vaginal Surgery: A Systematic Review. J Minim Invasive Gynecol, 2015. 22: 737.

https://www.ncbi.nlm.nih.gov/pubmed/25881881

575.Guenaga, K.F., et al. Mechanical bowel preparation for elective colorectal surgery. Cochrane Database Syst Rev, 2011. 2011: CD001544.

https://www.ncbi.nlm.nih.gov/pubmed/21901677

576.Dumville, J.C., et al. Preoperative skin antiseptics for preventing surgical wound infections after clean surgery. Cochrane Database Syst Rev, 2015. 2015: CD003949.

https://www.ncbi.nlm.nih.gov/pubmed/25897764

577.Webster, J., et al. Use of plastic adhesive drapes during surgery for preventing surgical site infection. Cochrane Database Syst Rev, 2015. 2015: CD006353.

https://www.ncbi.nlm.nih.gov/pubmed/25901509

578.Bonkat, G., et al. Non-molecular Methods to Detect Bacteriuria Prior to Urological Interventions: A Diagnostic Accuracy Systematic Review. Eur Urol Focus, 2017. 3: 535.

https://www.ncbi.nlm.nih.gov/pubmed/29627196

579.ECDC. Systematic review and evidence-based guidance on perioperative antibiotic prophylaxis. 2013.

https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/Perioperative%20antibiotic%20prophylaxis%20-%20June%202013.pdf

580.Antibacterial prophylaxis in surgery: 2 - Urogenital, obstetric and gynaecological surgery. Drug Ther Bulletin, 2004. 42: 9.

https://www.ncbi.nlm.nih.gov/pubmed/15067952

581.Benseler, A., et al. Antibiotic prophylaxis for urodynamic testing in women: a systematic review. Int Urogynecol J, 2021. 32: 27.

https://www.ncbi.nlm.nih.gov/pubmed/32845398

582.Foon, R., et al. Prophylactic antibiotics to reduce the risk of urinary tract infections after urodynamic studies [Systematic Review]. Cochrane Database Syst Rev, 2012. 10: 10.

https://www.ncbi.nlm.nih.gov/pubmed/23076941

583.Carey, M.M., et al. Should We Use Antibiotic Prophylaxis for Flexible Cystoscopy? A Systematic Review and Meta-Analysis. Urol Int, 2015. 95: 249.

https://www.ncbi.nlm.nih.gov/pubmed/26138144

584.Garcia-Perdomo, H.A., et al. Efficacy of antibiotic prophylaxis in cystoscopy to prevent urinary tract infection: a systematic review and meta-analysis. Int Braz J Urol, 2015. 41: 412.

https://www.ncbi.nlm.nih.gov/pubmed/26200530

585.Zeng, S., et al. Antimicrobial agents for preventing urinary tract infections in adults undergoing cystoscopy. Cochrane Database Syst Rev, 2019. 2: CD012305.

https://www.ncbi.nlm.nih.gov/pubmed/30789676

586.Bradshaw, A.W., et al. Antibiotics are not necessary during routine cystoscopic stent removal: A randomized controlled trial at UC San Diego. Urol Ann, 2020. 12: 373.

https://www.ncbi.nlm.nih.gov/pubmed/33776335

587.Lu, Y., et al. Antibiotic prophylaxis for shock wave lithotripsy in patients with sterile urine before treatment may be unnecessary: a systematic review and meta-analysis. J Urol, 2012. 188: 441.

https://www.ncbi.nlm.nih.gov/pubmed/22704118

588.Mrkobrada, M., et al. CUA Guidelines on antibiotic prophylaxis for urologic procedures. Can Urol Assoc J, 2015. 9: 13.

https://www.ncbi.nlm.nih.gov/pubmed/25737749

589.Hsieh, C.H., et al. The Effectiveness of Prophylactic Antibiotics with Oral Levofloxacin against Post-Shock Wave Lithotripsy Infectious Complications: A Randomized Controlled Trial. Surg Infect (Larchmt), 2016. 17: 346.

https://www.ncbi.nlm.nih.gov/pubmed/26910613

590.Shafi, H., et al. Antibiotic prophylaxis in the prevention of urinary tract infection in patients with sterile urine before extracorporeal shock wave lithotripsy. Caspian J Intern Med, 2018. 9: 296.

https://www.ncbi.nlm.nih.gov/pubmed/30197776

591.Lin, H.Y., et al. Atomoxetine Treatment Strengthens an Anti-Correlated Relationship between Functional Brain Networks in Medication-Naive Adults with Attention-Deficit Hyperactivity Disorder: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Int J Neuropsychopharmacol, 2015. 19: pyv094.

https://www.ncbi.nlm.nih.gov/pubmed/26377368

592.Deng, T., et al. Antibiotic prophylaxis in ureteroscopic lithotripsy: a systematic review and meta-analysis of comparative studies. BJU Int, 2018. 122: 29.

https://www.ncbi.nlm.nih.gov/pubmed/29232047

593.Zhao, Z., et al. Recommended antibiotic prophylaxis regimen in retrograde intrarenal surgery: evidence from a randomised controlled trial. BJU Int, 2019. 124: 496.

https://www.ncbi.nlm.nih.gov/pubmed/31136070

594.Qiao, L.D., et al. Evaluation of perioperative prophylaxis with fosfomycin tromethamine in ureteroscopic stone removal: an investigator-driven prospective, multicenter, randomized, controlled study. Int Urol Nephrol, 2018. 50: 427.

https://www.ncbi.nlm.nih.gov/pubmed/29290000

595.Yu, J., et al. Antibiotic prophylaxis in perioperative period of percutaneous nephrolithotomy: a systematic review and meta-analysis of comparative studies. World J Urol, 2020. 38: 1685.

https://www.ncbi.nlm.nih.gov/pubmed/31562533

596.Seyrek, M., et al. Perioperative prophylaxis for percutaneous nephrolithotomy: randomized study concerning the drug and dosage. J Endourol, 2012. 26: 1431.

https://www.ncbi.nlm.nih.gov/pubmed/22612061

597.Tuzel, E., et al. Prospective comparative study of two protocols of antibiotic prophylaxis in percutaneous nephrolithotomy. J Endourol, 2013. 27: 172.

https://www.ncbi.nlm.nih.gov/pubmed/22908891

598.Omar, M., et al. Ciprofloxacin infusion versus third generation cephalosporin as a surgical prophylaxis for percutaneous nephrolithotomy: a randomized study. Cent European J Urol, 2019. 72: 57.

https://www.ncbi.nlm.nih.gov/pubmed/31011442

599.Taken, K., et al. Comparison of Ceftriaxone and Cefazolin Sodium Antibiotic Prophylaxis in Terms of SIRS/Urosepsis Rates in Patients Undergoing Percutaneous Nephrolithotomy. J Urol Surg, 2019. 6: 111.

https://jurolsurgery.org/articles/comparison-of-ceftriaxone-and-cefazolin-sodium-antibiotic-prophylaxis-in-terms-of-sirsurosepsis-rates-in-patients-undergoing-percutaneous-nephrolithotomy/doi/jus.galenos.2018.2367

600.Dahm, P., et al. Evidence-based Urology. BMJ Books London, 2010: 50.

601.Bausch, K., et al. Antimicrobial Prophylaxis for Postoperative Urinary Tract Infections in Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-Analysis. J Urol, 2021. 205: 987.

https://www.ncbi.nlm.nih.gov/pubmed/33284673

602.Yang, J., et al. Prospective, randomized controlled study of the preventive effect of fosfomycin tromethamine on post-transurethral resection of bladder tumor urinary tract infection. Int J Urol, 2018. 25: 894.

https://www.ncbi.nlm.nih.gov/pubmed/29999216

603.Sanaee, M.S., et al. Urinary tract infection prevention after midurethral slings in pelvic floor reconstructive surgery: A systematic review and meta-analysis. Acta Obstet Gynecol Scand, 2019. 98: 1514.

https://www.ncbi.nlm.nih.gov/pubmed/31112286

604.Crawford, D., et al. Infectious Outcomes from Renal Tumor Ablation: Prophylactic Antibiotics or Not? Cardiovasc Intervent Radiol, 2018. 41: 1573.

https://www.ncbi.nlm.nih.gov/pubmed/30062444

605.Ploussard, G., et al. Transperineal Versus Transrectal Magnetic Resonance Imaging–targeted Biopsies for Prostate Cancer Diagnosis: Final Results of the Randomized PERFECT trial (CCAFU-PR1). Eur Urol Oncol, 2024. 7: 1080.

https://www.sciencedirect.com/science/article/pii/S258893112400049X

606.Mian, B.M., et al. Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial. J Urol, 2024. 211: 205.

https://www.ncbi.nlm.nih.gov/pubmed/37976319

607.Hu, J.C., et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol, 2024. 86: 61.

https://www.ncbi.nlm.nih.gov/pubmed/38212178

608.Hu, J.C., et al. Transperineal vs Transrectal Prostate Biopsy—The PREVENT Randomized Clinical Trial. JAMA Oncol, 2024. 10: 1590.

https://doi.org/10.1001/jamaoncol.2024.4000

609.Pradere, B., et al. Nonantibiotic Strategies for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis. J Urol, 2021. 205: 653.

https://www.ncbi.nlm.nih.gov/pubmed/33026903

610.Lam, W., et al. Abstracts of the Hong Kong Urological Association 26th Annual Scientific Meeting, Hong Kong, 17 October 2021. BJU Int, 2022. 129 Suppl 1: 4.

https://www.ncbi.nlm.nih.gov/pubmed/35202507

611.Bennett, H.Y., et al. The global burden of major infectious complications following prostate biopsy. Epidemiol Infect, 2016. 144: 1784.

https://www.ncbi.nlm.nih.gov/pubmed/26645476

612.Berry, B., et al. Comparison of complications after transrectal and transperineal prostate biopsy: a national population-based study. BJU Int, 2020. 126: 97.

https://www.ncbi.nlm.nih.gov/pubmed/32124525

613.Castellani, D., et al. Infection Rate after Transperineal Prostate Biopsy with and without Prophylactic Antibiotics: Results from a Systematic Review and Meta-Analysis of Comparative Studies. J Urol, 2022. 207: 25.

https://www.ncbi.nlm.nih.gov/pubmed/34555932

614.Basourakos, S.P., et al. Role of Prophylactic Antibiotics in Transperineal Prostate Biopsy: A Systematic Review and Meta-analysis. Eur Urol Open Sci, 2022. 37: 53.

https://www.ncbi.nlm.nih.gov/pubmed/35243391

615.Chernysheva, D.Y., et al. The first experience of transperineal prostate biopsy without antibiotic prophylaxis. Cancer Urol, 2021. 17: 46.

https://www.researchgate.net/publication/353446695

617.Shaker, H.S., et al. Does The Use Of Povidone Iodine Suppository Decrease The Infective Complications Of TRUS Guided Prostate Biopsies? A Randomized Prospective Study. QJM: Int J Med, 2020. 113.

https://academic.oup.com/qjmed/article/113/Supplement_1/hcaa070.024/5829649

618.Ergani, B., et al. Effect of rectal mucosa cleansing on acute prostatitis during prostate biopsy: A randomized prospective study. Turk J Urol, 2020. 46: 159.

https://www.ncbi.nlm.nih.gov/pubmed/31922485

619.Farooq, K., et al. Role of Povidone-Iodine-Soaked Gauze in Preventing Infectious Complications Following Trans Rectal Digital Guided Prostate Biopsy. J Postgrad Med Inst, 2021. 35: 225.

https://jpmi.org.pk/index.php/jpmi/article/view/2849

620.Taher, Y., et al. (2014) Prospective randomized controlled study to assess the effect of perineal region cleansing with povidone iodine before transrectal needle biopsy of the prostate on infectious complications. Urology, 84: S306.

https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01023606/full

621.Yu, L., et al. [Impact of insertion timing of iodophor cotton ball on the control of infection complications after transrectal ultrasound guided prostate biopsy]. Zhonghua Yi Xue Za Zhi, 2014. 94: 609.

https://www.ncbi.nlm.nih.gov/pubmed/24762693

622.Ezenwa, E.V., et al. Apical peri-prostatic nerve block versus intra-rectal xylocaine gel for trans- rectal ultrasound guided prostate biopsy among Nigerian patients: A prospective randomized study. Niger J Clin Pract, 2020. 23: 1183.

https://www.ncbi.nlm.nih.gov/pubmed/32913154

623.Jang, H., et al. Comparison of intrarectal heated lidocaine gel and periprostatic nerve block for pain control in transrectal ultrasound-guided prostate biopsy: A randomized controlled non-inferiority trial. Prostate Int, 2023. 11: 8.

https://www.ncbi.nlm.nih.gov/pubmed/36910899

624.Russo, F., et al. MR-TARGETED VS. TRUS-GUIDED PROSTATE BIOPSY IN PATIENTS WITH HIGH PSA VALUES: A RANDOMIZED CONTROLLED TRIAL. Anticancer Research, 2016. 36: 2556.

https://ar.iiarjournals.org/content/anticanres/36/5/2535.full.pdf

625.Pilatz, A., et al. Antibiotic Prophylaxis for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis. J Urol, 2020. 204: 224.

https://www.ncbi.nlm.nih.gov/pubmed/32105195

626.Bouzouita, A., et al. Antimicrobial prophylaxis protocol based on rectal swab culture before prostate biopsy to prevent infectious complications: a prospective randomized comparative study. Int Urol Nephrol, 2024. 56: 2495.

https://www.ncbi.nlm.nih.gov/pubmed/38448785

627.Supreeth, N., et al. Prospective randomized controlled study of comparing efficacy of prophylactic intraprostatic antibiotic injection with oral antibiotic verses standard oral prophylaxis in patients undergoing transrectal ultrasonography guided prostate biopsy. Indian J Urol, 2023. 39: S3.

628.Andreasson, A., et al. Fosfomycin versus Ciprofloxacin as transrectal prostatebiopsy antibiotic prophylaxis – an open randomized controlled multicenter drug trial. Eur Urol, 2023. 83: S180.

https://www.sciencedirect.com/science/article/abs/pii/S0302283823001835629

629.Carignan, A., et al. Effectiveness of fosfomycin tromethamine prophylaxis in preventing infection following transrectal ultrasound-guided prostate needle biopsy: Results from a large Canadian cohort. J Glob Antimicrob Resist, 2019. 17: 112.

https://www.ncbi.nlm.nih.gov/pubmed/30553114

630.Pilatz, A., et al. European Association of Urology Position Paper on the Prevention of Infectious Complications Following Prostate Biopsy. Eur Urol, 2021. 79: 11.

https://www.ncbi.nlm.nih.gov/pubmed/33172721

About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer